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ABSTRACT 
Zhong Yan 
ONTOLOGY-DRIVEN AND NTEWORK–ENABLE  
SYSTEMS BIOLOGY CASE STUDIES 
 
     With the progress in high-throughput technologies and bioinformatics in recent years, 
it is possible to determine to what extent genetic or environmental manipulation of a 
biological system affects the expression of thousands of genes and proteins. This study 
requires a shift from the conventional pure hypothesis-driven approach to an integrated 
approach--systems biology method. Systems biology studies the relationships and 
interactions between various parts of a biological system. It allows individual genes or 
proteins to be placed in a global context of cellular functions. This analysis can answer 
the question of how networks of genes/proteins, differentially regulated respond to 
genetic or environmental modification, are placed in the global context of the protein 
interaction map. In this project, we establish a protein interaction network-based systems 
biology approach, and use the method for two case studies.  
 
     In particular, our systems biology studies consist of the following parts: (1) Analysis 
of mass-spectrometry derived proteomics experimental data to identify differentially 
expressed proteins in different genetic or environmental conditions; (2) Integration of 
genomics and proteomics data with experimental results, the molecular context of 
protein-protein interaction networks and gene functional categories; (3) Visual 
interpretation of molecular networks. Our approach has been validated in two case 
studies by comparing our discoveries with existing findings. We also obtained new 
insights. In the first case study, the proteomes of cisplatin-sensitive and cisplatin-resistant 
ovarian cancer cells were compared and we observed that cellular physiological process 
is significantly activated in cisplatin-resistant cell lines, and this response arises from 
endogenous, abiotic, and stress-related signals. We found that cisplatin-resistant cell lines 
demonstrated unusually high level of protein-binding activities, and a broad spectrum of 
across-the-board drug-binding and nucleotide-binding mechanisms are all activated. In 
 vi 
the second case study, we found that the significantly enriched GO categories included 
genes that are related to Grr1 perturbation induced morphological phenotype change are 
highly connected in the GO sub-network, which implies that Grr1 could be affecting this 
process by affecting a small core group of proteins. These biological discoveries support 
the significance of developing a common framework of evaluating functional genomics 
and proteomics data, using networks and systems approaches.  
 vii 
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1. INTRODUCTION 
 
     Over the past two centuries, life science research has been rooted in the assumption 
that complex problems may be solvable by dividing them into smaller, simpler, and 
thus more manageable units. While the human body is considered to be an integrated 
system with a company of components, the natural tendency of medicine is to separate 
the single factor that is most responsible for the consequence. It is undeniable that this 
approach has been a success for years. However, it leaves little room for contextual 
information. The need to make sense of complex interactions has led some researchers 
to shift from a component-level to system-level perspective. With the progress in high-
throughput technologies and bioinformatics (for example, many bioinformatics 
databases are available to the public) in recent years, it is possible to determine to 
what extent genetic or environmental manipulation of a biological system affects the 
expression of thousands of genes and proteins. This form of study requires a shift from 
a conventional individual approach (divide-and-conquer approach) towards an 
integrated approach. The integrated approach leads to an emerging field called 
systems biology[1]. Systems biology takes into account complex interactions of genes, 
proteins, and cell elements. By studying the relationships and interactions between 
various parts of a biological system, it is hoped that researchers might build a system-
level understanding of biological systems and gain novel insights towards discoveries. 
 
     In this project, we have developed a novel systems biology approach to study 
proteomics experimental data. Using this approach we have performed case studies on 
two proteomics datasets: (1) human ovarian cancer drug resistance; (2) yeast Grr1 
knock-out. Our systems biology studies consist of the following parts (see figure 1.1). 
(1) Analyzing mass-spectrometry derived proteomics experimental data to identify 
differentially expressed proteins in cisplatin-sensitive vs. cisplatin-resistant ovarian 
cell line samples and yeast Grr1 knock-out vs. wild-type samples; (2) Integrating 
genomics and functional genomics data with experimental results and the molecular 
context of protein-protein interaction networks and gene functional categories: we use 
OPHID (Online Predicted Human Interaction Database) for our ovarian cancer study 
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and an in-house developed yeast protein-protein interaction database (SBG) for our 
yeast study. The integration involves identifying protein interaction partners for the 
differentially-expressed protein set ("seed proteins"), as well as identifying the gene 
ontology cross-talk partners in the context of the protein-protein interaction network; 
(3) Visual interpretation of molecular networks.[2] 
 
 
 
Figure 1.1 Framework of novel systems biology approach 
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     Unlike conventional methods, which lack functional integration of data and 
effective analysis tools to derive functional relationships between heterogeneous while 
related data, our studies have the following significance. First, we have developed a 
novel systems biology approach which can identify “significantly interacting protein 
categories”. This is distinct from the recent approach of using GO annotations for 
differentially expressed gene classifications resulting from microarray analysis[3]. Our 
method can be generalized to enable other similar systems biology studies, in which 
statistically significant experimental “omics” results, public protein interactome data, 
and genome/proteome annotation database are integrated into an easy-to-interpret two-
dimensional visualization matrix[2]. Second, to integrate yeast protein-protein 
interaction data from different sources, we have created our own metadata for 
experimental methods that are used to detect interacting protein pairs (see section 3.2 
in paragraph “Protein Interactome Data”). Third, we have developed our unique 
scoring model (see section 3.3) to calculate reliability scores for the interacting protein 
pairs. We applied our scoring model to the combined protein-protein interaction 
dataset to calculate a reliability score for each unique interacting pair. This enables our 
significant protein ranking analysis (see section 3.10). Fourth, we applied a unique 
molecular network visual representation scheme to the significant biological process 
categories and significant between-category interactions (see section 3.5 and section 4. 
for two case studies). Our new approach based analysis will help the life science 
researchers validate their discoveries and generate new hypotheses. 
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2. BACKGROUND 
 
2.1 Mass Spectrometry - based Proteomics 
     Proteomics refers to the branch of discovery science focusing on large scale 
analysis of proteins. Initially, the term proteomics was used to describe the study of 
expressed proteins of a genome using a combination of two-dimensional (2D) gel 
electrophoresis to separate proteins and mass spectrometry (MS) to identify them.  
This approach is now referred to as “expression” or “global profiling” proteomics. 
However, the scope of proteomics has now broadened to include the study of “protein-
protein” interactions (protein complexes), referred to as cell-mapping proteomics [4, 
5]. Proteomics complements other functional genomics, including microarray 
expression profiling, systematic phenotypic profiling, systematic genetics, and small-
molecule-based arrays [6]. Compared with genomics, proteomics is much more 
complicated.  While the genome is rather stable, the proteome differs from cell to cell 
and is constantly changing through its biochemical interactions with the genome and 
the environment.  
 
     Mass spectrometry-based proteomics has a distinct application in unraveling the 
levels of protein abundance, post-translational modifications (e.g., glycosylation, 
acetylation, phosphorylation, and myristoylation), as well as protein-protein 
interactions, which are the formative drive in a cell. Changes in these parameters are 
not revealed by measuring mRNA levels. Mass spectrometry-based proteomics 
provides opportunities to identify target proteins that are differentially regulated under 
different conditions. It helps biologists elucidate the dynamics of important signaling 
and regulatory networks in biological process.  
 
2.1.1 Mass spectrometry 
     Mass spectrometry is the method for determining the molecular weight of chemical 
compounds by separating molecular ions according to their mass-to-charge ratio (m/z).  
Mass spectrometers are powerful devices used for this purpose. Mass spectrometric 
measurements are carried out in the gas phase on ionized analytes. A mass 
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spectrometer consists of an ionization source for ion-generation, a mass analyzer that 
measures the mass-to-charge ratio (m/z) of the ionized analytes, and a detector that 
registers the number of ions at each m/z value. The ionization source transfers 
molecules from solution or solid phase into gas-phase ions that can then be 
manipulated within electric or magnetic fields. Ionization techniques are critical for 
determining what types of samples can be analyzed by mass spectrometry. The two 
most frequently used ionization techniques are ESI (Electrospray Ionization) and 
MALDI (Matrix-Assisted Laser Desorption/Ionization). ESI ionizes the analytes out 
of a solution and is therefore readily coupled to liquid-based separation tools such as 
HPLC. MALDI sublimates and ionizes the samples out of a fry, crystalline matrix via 
laser pulses. MALDI-MS is normally used to analyze relatively simple peptide 
mixtures, whereas integrated liquid-chromatography ESI-MS systems (LC-MS) are 
preferred for the analysis of complex samples [7, 8]. 
 
     The mass-analyzer is used to separate gas-phase ions based on their mass-to-charge 
(m/z) ratios, and is central to the technology. In the context of proteomics, its key 
parameters are sensitivity, resolution, mass accuracy and its ability to generate 
information-rich ion mass spectra from peptide fragments (tandem mass or MS-MS 
spectra). There are four basic types of mass analyzers currently used in proteomics 
research. These are the ion trap, time-of-flight (TOF), quadrupole, and Fourier 
Transform ion cyclotron (FT-ICR-MS) analyzers. They are very different in design 
and performance and, each has its own strength and weakness. These analyzers can be 
stand alone or, in some cases, put in tandem to take advantage of the strengths of each 
[8-11]. 
 
     Both MALDI and ESI are soft ionization techniques in that ions are created with 
low internal energy and thus undergo little fragmentation. Mass-to-charge ratios can 
be readily and accurately measured for intact ions, but this information does not 
provide data on the covalent structure of the ion. For peptides and proteins in 
particular, data related to the amino acid sequence of the molecule are desired. To 
generate this information, new configurations of mass spectrometers have been 
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developed to isolate ions, fragment them, and then measure the mass-to-charge ratio of 
the fragments. These devices are collectively called tandem mass spectrometers. A 
tandem mass spectrometer is a mass spectrometer that has more than one analyzer, in 
practice usually two. The two analyzers are separated by a collision cell into which an 
inert gas (e.g. argon, henium) is admitted to collide with the selected sample ions and 
bring about their fragmentation (collision-induced dissociation or CID). The analyzers 
can be of the same or different types, the most combinations being quadrupole-
quadrupole, magnetic sector-quadrupole, and quadrupole-TOF [12, 13]. 
 
     The first analyzer of a tandem mass spectrometer is used to select user-specific 
peptide ions from peptide mixtures. These chosen ions then pass into the collision cell, 
and are bombarded by the gas molecules into fragment ions, which are then analyzed. 
The original mass to charge ratio of each ion as well its specific fragment spectrum are 
used to search a database of theoretical peptide fragmentation spectra often resulting 
in unambiguous peptide identification. The data from each of these methodologies is 
represented as output peak list files adherent to a specific file format that is dependent 
on the instrument used for analysis. Programs such as SEQUEST [14] and MASCOT 
(http//www.matrixscience.com) correlate the experimentally acquired MS/MS spectra 
to the computer generated MS/MS spectra and produce various scores used to assess 
the validity of this correlation. Each correlation program uses a different algorithm to 
assign peptides and thus each program produces overlapping but variable outputs. 
Various laboratories have used different approaches to exploit the advantages of both 
software algorithms [15] and to validate more thoroughly the results of these 
algorithms individually [16, 17]. It is apparent that no single analysis system has been 
universally accepted to date. 
 
2.1.2 Proteomics data analysis 
     In a typical mass spectrometry based experiment, protein samples are digested by a 
protease (usually trypsin) and the resulting peptides can be further separated by liquid 
chromatography before directly introduced into MS. The peptide fragment masses are 
determined by MS, which provides a fingerprint of the protein of interest. The masses 
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are compared to the predicted proteolytic peptides from sequence databases taking into 
account user specified parameters such as the number of missed cleavage sites. If, 
however, database searching leads to ambiguous results, then further MS analyses, 
involving the usage of tandem mass spectrometry (MS/MS), are undertaken 
sequentially on each peptide in the mixture to generate a sequence, or partial sequence, 
known as a sequence tag, for these peptides. This is frequently achieved by using ESI-
MS/MS. Further database searching with both the molecular mass of the peptide and 
the sequence tag information should lead to unambiguous protein identification[18-20]. 
Finally, the instrument generates an output peak list file in a specific file format 
depending on the type of instrument used, and an analysis pipeline (Figure 2.1) can be 
used to take the peak list file as input and generate a series of output files.  
 
 
Figure 2.1 Proteomics data analysis pipeline 
2.1.3 Proteomics data management tools 
     The scale and complexity of proteomics data require software tools to facilitate 
data management. Compared with microarray data management tools, there are few 
tools available for mass spectrometry proteomics studies. Below we summarize most 
of the proteomics data management tools. This work is based on my previous 
publication [21]. 
 
     PEDRo database tool (http://pedro.man.ac.uk ) is an open source tool for 
proteomics data entry and modeling. However, it is not a comprehensive query and 
analysis tool. The PEDRo tool implements the PEDRo data model (Refer to section 3) 
which was released early in 2003. The schema of the PEDRo data model is available 
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at the website. PEDRo supports an ontology service. It stores the XML directly in an 
open-source XML storage system, Xindice. The data are presented to the users by 
gathering web pages from the stored XML using XSLT.[22, 23] 
 
SBEAMS-Proteomics (http://www.sbeams.org/Proteomics/ ) is one of the modules of 
SBEAMS integrated platform developed by ISB that is used for proteomics 
experimental data storage and retrieval. These experiments can be correlated later 
under the same framework. The integrated open source system SBEAMS adopts a 
relational database management system backend and a web interface front end. 
Information about the quality of identification can be stored with the data; peptides 
which could not be properly identified from mass spectra can be flagged and 
reanalyzed with additional searches. The database schema for SBEAMS-Proteomics is 
available at the website (http://www.sbeams.org/Proteomics/ ).  
 
     ProteinScape is a commercial client-server platform for proteomics data 
management (http://www.bdal.com/proteinscape.html). It organizes data such as gel 
data, mass spectra, process parameters, and search results. It can manage gel-based or 
LC-based workflows, as well as quantitative proteomics. ProteinScape also enables 
automated analysis through interactions with database search engines such as Mascot, 
Phenux, and Profound. ProteinScape‟s relational database system can be Microsoft 
SQL or Oracle 9.1.  
 
     PROTEIOS (http://www.proteios.org/) is an mzData-compliant open source client-
server application that implements mass spectrometry data storage, organization, and 
annotation. The server is a relational database that can be MySQL, Oracle, as well as 
utilize other alternatives. The client side runs as a Java application. One of the main 
objectives of Proteios is to provide a GUI enabling queries based on experiment data 
and annotation data. The schematic diagram is available at the website. Currently the 
input data files must be in XML format.  It is working on imports of tab-separated files 
[24]. 
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     PROTICdb is a web-based proteomics data management tool used for plant 
proteomics data storage and analysis. The data can come from 2D-GEL and MS. The 
data stored can also be in the form of quantitative measurements. To support data 
interpretation, PROTICdb allows the integration of information from the user‟s own 
expertise and other sources into a knowledge base. It also provides links to external 
databases [25]. 
 
     ProDB is an open source proteomics data management tool 
(http://www.cebitec.uni-bielefeld.de/groups/brf/software/prodb_info/index.html) that 
can handle data conversion between different mass spectrometer software, automate 
data analysis, and allow the annotation of MS spectra (i.e. assigning gene names or 
storing data on protein modifications). The system is based on an extensive relational 
database to store the mass spectra together with the experimental setup [26]. The first 
release will be available to the public soon. 
 
     There are several other proteomics data management tools not described here, such 
as PROTEUS [27], Proteomics Rims (developed by Bruker BioSciences), Xome and 
Mass Navigator [28]. 
 
2.2 Ontology-based Gene Annotation and Network-enabled Analysis  
 
2.2.1 Proteomics and Systems Biology 
     The goal of proteomics research is to understand the expression and function of 
proteins on a global level. It strives to characterize protein structure and function, 
protein-protein, protein-nucleic acid, protein-lipid, and enzyme-substrate interactions, 
post-translational modifications, protein processing and folding, protein activation, 
cellular and sub-cellular localization, protein turnover and synthesis rates, and even 
alternative isoforms caused by differential splicing and promoter usage. In addition, 
the ability to capture and compare all of this information between two cellular states is 
essential for understanding cellular responses. Achieving the goals of proteomics is 
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not trivial. Adding to the complexity of this field is the need to integrate proteomics 
data with other information to fully understand how systems work.  
 
     Systems biology is a newly emerging field that seeks to analyze the relationships 
among elements in a system in response to genetic or environmental perturbations, 
with the goal of understanding the system or the properties of the system[29]. 
Therefore, systems biology is a holistic approach that seeks to integrate biological data 
as an attempt to understand how biological systems function, thus being distinct from 
a pure omics - based or other bioinformatics methods.  The present thesis is an attempt 
in this direction. We captured the proteome difference between cellular states, and 
integrate this information with information from gene ontology as well as protein 
interaction database. Thus, for the first time, it provides an in-depth interpretation at 
the molecular signaling network level. 
 
     In particular, our systems biology approach consists of the following three major  
elements [2]: (1) Omics: analyzing mass-spectrometry derived proteomics 
experimental data to identify differentially expressed proteins in different genetic or 
environmental conditions; (2) Ontology: annotating the proteomics data based on gene 
ontology functional categories; (3) Network: mapping the proteomic data into protein-
protein interaction network and translating the protein-protein interaction network into 
a gene ontology cross-talk network.  
 
 
 
Figure 2.2 Major elements of our systems biology approach. The lines represent 
the tight connections of the elements.   
 
Proteomics  
(see 2.1.1 ~ 
2.1.3) 
Gene 
Ontology 
(see 2.2.2) 
Protein - Protein 
Interaction Network 
(see 2.2.3 and 3.2) 
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     Figure 2.2 shows the three major elements of our systems biological approach. In 
this approach, the data from omics experimental results is analyzed against gene 
functional categories and gene functional category network. It is the first time that the 
gene ontology concept has been brought to the molecular context of protein-protein 
interaction networks, which has been used to interpret the proteomics experimental 
result.  
 
2.2.2 Ontology – based gene annotations 
     From the point of view of systems biology, the interpretation of differentially 
expressed protein lists identified from proteomics experiments is not a trivial task. 
Given a set of differentially expressed genes / proteins, or a set of genes / proteins in a 
cluster, one would often wish to know whether these genes / proteins share a common 
function, subcellular localization, metabolic or regulatory pathway. In addition to 
characterizing the gene/protein set, this type of analysis may also reveal information 
on new and previously unknown genes in the set. This type of work often requires the 
mapping of the genes/proteins into gene ontology (GO) terms. The introduction of 
Gene Ontology (GO) as a standardized vocabulary for describing genes, gene products 
and their biological functions represents an important milestone in the possibilities to 
handle and include biological background information in functional genomics and 
proteomics analyses. 
 
     The gene ontology is represented as a network, or a „directed acyclic graph‟ (DAG), 
in which terms may have multiple parents and multiple relationships to their parents. 
The controlled vocabularies are structured in levels so that attributes can be assigned 
to a gene product at different levels of description, depending on how much is known 
about this gene product.[30] There are three different sets of vocabularies for gene 
ontology: (1) Molecular function describes the activity of a gene product at the 
molecular level. It does not provide information about the compounds or locations of 
the activity. Example of molecular function at level 2 can be binding and at level 3 can 
be protein binding. The more specific term at level 4 can be transcription factor 
binding. (2) Biological process describes recognized series of events or molecular 
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functions. A biological process is not equivalent to a pathway though some GO terms 
do describe pathways. Examples of biological process are death at level 3 and cell 
death at level 4. (3) Cellular component refers to the location in the cell in which a 
gene product exerts its activity. Examples are nucleolus, organelle, and polarisome. 
Many databases today provide GO annotations for a variety of organisms including 
humans, yeast, and other species. 
 
     Annotation of genes with GO terms creates a biological knowledge profile in three 
layers (biological process, molecular function, or cellular component). Three common 
methods are used to query GO categories: by individual gene, by gene function, and 
by using a list of genes [31]. Translation of the differentially expressed gene/protein 
list into a functional profile helps biologist get insight into the cellular mechanisms 
relevant to a given condition. Therefore, it has been widely used in the analysis of 
functional genomics and proteomics studies [32-36].  
 
     The ontological analysis of gene expression or proteomics data usually follows the 
following steps: (1) Prepare the gene or protein list of interest. (2) Prepare reference 
gene or protein list which is used to calculate P-values against. (3) Map both lists 
(interested list and reference list) to GO categories. (4) Select statistical model. The 
gene ontology analysis can be performed with a number of statistical models including 
hypergeometric, binomial, Fisher‟s exact test, and chi-square. These tests are 
discussed in detail in [37]. (5) Find significantly enriched GO categories in your list of 
interest using the selected statistical model. (6) Perform corrections for multiple 
comparisons. When many genes/proteins are analyzed at the same time, some 
significance will happen by chance. The multiple comparison corrections control the 
overall probability of making a Type I error. Many different statistical methods have 
been published to perform this kind of correction, for example, Bonferroni correction 
[38], FDR [39], and permutation correction [40]. Each method has its unique feature. 
(7) Interpret the result in terms of the biological significance. 
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     The statistical evaluation of enriched GO categories enables to highlight the most 
significant biological characteristics of a gene or protein set, therefore allows us to 
mine knowledge from data. In recent years, many tools have been developed to 
automate the gene ontology analysis. Table 2.1 lists some popular GO analysis tools, 
the statistical models the tools used, multiple comparison correction methods 
implemented, and the GO visualization view. 
 
Table 2.1 Gene Ontology analysis tools 
Tool Statistical model Multiple comparison 
corrections 
GO 
visualization 
WebGestalt[41] Hypergeometric test, 
Fisher‟s exact test 
NA Tree, bar chart, 
DAG  
GeneMerge[42] Hypergeometric Bonferroni No tree view 
CLENCH[43] Chi-square test, Binomial, 
Hypergeometric 
NA DAG 
GOSurfer[44] Chi-square test FDR Tree 
Onto-
Express[45] 
Chi-square test, Binomial, 
Hypergeometric, Fisher‟s 
exact test 
Bonferroni, Holm, 
Sidak 
Tree 
GOToolBox[46] Binomial, Hypergeometric, 
Fisher‟s exact test 
Bonferroni, 
Holm,FDR, Hochberg, 
Hommel, 
NA 
Onto-
Express[45, 47] 
Binomial, Hypergeometric, 
Chi-square test 
Bonferroni, Holm, 
Sidak, FDR 
Tree, bar chart 
GO Term 
Finder[48] 
Binomial NA Tree 
 
     The ontology-based omics data analysis approach enables researchers to find out 
enriched functional categories involved in the experimental conditions. While 
biological systems contain large number of different genes and proteins that are 
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interacted with each other, it is necessary to develop an approach to bring the 
ontology-based omics data analysis to the interaction network. This integrated 
approach will definitely benefit the biologists to obtain more insight for biological 
phenomena. 
 
2.2.3 Protein interaction network- based analysis 
     A discrete biological function is rarely attributable to an individual protein [49]. 
Instead, most biological characteristics arise from complex interactions between the 
cell‟s numerous constituents, such as proteins, DNA, RNA and small molecules. In 
particular, the network of protein-protein interactions, also referred to as interactome, 
forms a backbone of signaling pathways, metabolic pathways and cellular processes 
for normal cell function. Protein interaction network analysis provides an effective 
way to understand the relationships between genes. It places the genes identified in 
functional genomics and proteomics experiments in a broader biological context, 
thereby facilitating the understanding of the structure and function of a living cell.  
 
     The network-based analysis has been enabled by the recent elucidation of large-
scale protein interaction networks in different species, including S. cerevisiae 
(yeast)[50-53], D. melanogaster (fly)[54], C. elegans (worm)[55] and H. sapiens 
(human)[56, 57]. )[56, 57]. Collections of these protein interactions, representing a 
subset of the whole interactome, are stored in various data repositories as the Database 
of Interacting Proteins (DIP) (ref), the Biomolecular Interaction Database (BIND), 
The Molecular INTeraction Database (MINT), InAct, the human Protein Reference 
Database (HPRD) and the  Online Predicted Human Interaction Database (OPHID) 
[58]. The protein network-based analysis has been utilized for the analysis of  
functional genomics experiments recently [59, 60]. 
 
     The most comprehensive database for a human protein network is the Online 
Predicted Human Interaction Database (OPHID) [58]. OPHID
 
is a web-based database 
of predicted interactions between human
 
proteins. It combines the literature-derived 
human protein-protein interactions from
 
BIND (Biomolecular Interaction Network 
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Database), HPRD (Human Protein Reference Database) and MINT (Molecular 
Interactions Database), with predictions made from Saccharomyces
 
cerevisiae, 
Caenorhabditis elegans, Drosophila melanogaster
 
and Mus musculus. OPHID 
catalogs 16034 known
 
human PPIs obtained from BIND, MINT and HPRD, and 
makes predictions
 
for 23889 additional interactions.[58]
  
It is designed to be both a 
resource for the laboratory scientist to explore known and predicted protein-protein 
interactions, and to facilitate bioinformatics initiatives exploring protein interaction 
networks. It should be noted that OPHID predicted human interaction are hypothetical 
and are likely to have some false positives as well as missing protein interactions. 
However, it was claimed that approximately half of the predicted interactions using 
interlogs between microorganisms can be experimentally validated [61]. 
Table 2.2 Leading protein interaction databases 
Name     Description 
Online Predicted Human Interaction Information about known human PPIs from Database 
(OPHID) http://ophid.utoronto.ca/ophid/    BIND, MINT, and HPRD, as well as large 
     number of  predicted human PPIs 
Human Protein Reference Database        Manually curated and extracted from literature  
(HPRD) http://www.hprd.org/  for human PPIs 
Saccharomyces Genome Database          Comprehensive database that contains genetic  
(SGD) http://www.yeastgenome.org/ and physical interactions for yeast  proteins.  
                                                                 More than 90% interactions come from GRID 
General Repository for Interaction         Genetic and physical interactions for yeast, fly,  
Datasets (GRID)  and worm proteins. Interactions data comes from                                  
http://biodata.mshri.on.ca/grid literature, BIND, and MIPS, including several 
genome/proteome-wide studies 
Biomolecular Interaction Network          Physical, biochemical, genetic interactions, and  
Database (BIND) interactions between DNA, RNA, proteins, small 
http://www.isc.org/index.pl?/sw/bind/ molecules, including interactions from human, yeast, 
mouse, rat, and many other species. 
Human Annotated Protein Protein          Database that contains protein interactions from 
Interaction (HAPPI) String, OPHID, and HPRD. 
http://bio.informatics.iupui.edu/HAPPI/index.stm   
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     On the other hand, SGD (Saccharomyces Genome Database) is a scientific 
database of the molecular biology and genetics of the yeast Saccharomyces cerevisiae, 
which is commonly known as Baker's or budding yeast. Besides protein-protein 
interaction datasets, SGD also contains genes and proteins sequence information, 
descriptions and classifications of their biological roles, molecular functions, and 
subcellular localizations, and links to literature information (see table 2.2) [62-64]. 
More than 90% of the interactions stored in SGD come from GRID. BIND 
(Biomolecular Interaction Network Database) is the database that stores the 
interactions between DNA, RNA, proteins, and small molecules for many species 
including yeast [65-67].  Table 2.2 lists the information for the leading protein 
interaction databases. 
 
     The protein network-based analysis has been considered as one of the most 
important elements of the systems biology approach. Protein network analysis place 
the genes identified in microarray experiments or differentially expressed proteins 
detected in mass-spectrometry experiments in a global biological context. Protein-
protein interaction networks reflect the functional grouping of these coordinated 
genes/proteins. It enables the study of the roles of subsets of genes/proteins. 
 
     A few papers published recently reported mapping the differentially expressed 
protein lists identified through microarray or proteomics experiments into protein-
protein interaction database such as OPHID. Using the network-based analysis, Wachi 
et al found that the genes differentially elevated in cancer, as obtained from 
microarray profiling data, are well connected[60]. In this study, genes in the array 
were mapped onto OPHID using gene symbols and protein sequences. Connectivity 
analysis was performed for the protein network constructed. Then k-core analysis was 
conducted, where less connected nodes were removed in an iterative way. This 
resulted in a series of subgraphs that gradually revealed the globally central region of 
the original network. Using k-core analysis, the authors measured how differentially 
expressed genes were close to the topological center of the protein network. Centrality 
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of the genes is associated with the essential functions of the genes in the yeast. The 
analysis concluded that squamous cell lung cancer genes share similar topological 
features for essential proteins. 
 
     Calvano et al recently performed a network analysis of systematic inflammation in 
humans [68]. Gene expression patterns in human leukocytes receiving an 
inflammatory stimulus were first analyzed using genome-wide microarray analysis. 
Genes significantly perturbed after stimulus were identified using significance analysis 
of microarray method, which controls the false discovery rate to less than 0.1%. To 
identify significant pathways in a biological process, the differentially expressed genes 
were overlaid onto the interactome, the Ingenuity Pathways Knowledge Base (KB), 
which is the largest curated database of previously published findings on mammalian 
biology from the public literature. Target genes were identified as the subset having 
direct interactions with other genes in the database. The specificity of connections for 
each target gene was calculated by the percentage of its connections to other 
significant genes. Pathways of highly connected genes were identified by likelihood. 
Using this strategy, the authors demonstrated that, upon acute systematic inflammation, 
the human blood leukocyte response includes widespread suppression at the 
transcriptional level of mitochondria energy production and protein synthesis 
machinery.  
 
     Said, et al [69] used protein interaction networks to analyze the phenotypic effects 
in yeast. Toxicity-modulation, non-phenotypic classifications, and high-throughput 
genomic phenotyping were conducted. Networks that represented a phenotypically 
annotated interactome of essential, toxicity-modulating, and no-phenotype proteins 
were constructed. The analysis showed interesting results. For example, 
toxicologically important protein complexes, pathways, and modules were identified, 
which have potential implications for understanding toxicity-modulating processes 
relevant to human diseases. 
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     In other studies, Seiden-Long et al integrated the microarray datasets with OPHID 
and found six of the target genes by HGF/Met/RAS signaling belong to a hypothetical 
network of function at the protein level [70]. Motamed-Khorasani et al found that six 
of the total of 17 androgen-regulated genes could be mapped into OPHID database. 
Five of the six genes are networked within two interacting partners [71].  
 
     The current project will integrate the three elements: proteomics, ontology, and 
network, and perform ontology-driven and network-enabled systems biology case 
studies. The following sections will describe the details of our methods and results. 
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3. METHODS 
 
     All methods related to ovarian cancer study in this section were based on the 
published methods and private communications with Dr. Chen, Dr. Shen, and Dr. 
Wang. I am one of the primary contributing members (Chen, J., Yan, Y., Shen, C., 
Fitzpatrick, D., Wang, M. A Systems Biology Case Study of Ovarian Cancer Drug 
Resistance. JBCB, 2007[2].). Method in 3.2.2 was kindly provided by Dr. Shen, who 
developed a statistical model to identify differentially expressed proteins as one of the 
inputs of my case study 2.  Ovarian cancer proteomics experimental methods in 
section 3.1.1 were kindly provided by Dr. Mu Wang. Yeast proteomics experimental 
methods in section 3.1.2 were kindly provided by Josh Heyen. Tables 3.1 ~ 3.3 were 
based on discussion with Dr. Goebl and Josh Heyen, where I am one of the 
contributors. The use of the materials was granted with the permission from 
participating contributors. 
 
3.1 Proteomics Method 
3.1.1 Ovarian cancer drug resistance proteomics method  
     A2780 and 2008 cisplatin-sensitive human ovarian cancer cell lines and their 
resistant counterparts, A2780/CP and 2008/C13*5.25, were used in the ovarian cancer 
drug resistant study. Proteins were prepared and subjected to LC/MS/MS analysis as 
described in [72]. There were two groups (two different parent cell lines), six samples 
per cell line, and two HPLC injections per sample. Samples were run on a Surveyor 
HPLC (ThermoFinnigan) with a C18 microbore column (Zorbax 300SB-C18, 1mm x 
5cm). All tryptic peptides (100 L or 20 g) were injected onto the column in random 
order. Peptides were eluted with a linear gradient from 5 to 45% acetonitrile 
developed over 120 min at a flow rate of 50 L/min. Fluant was introduced into a 
ThermoFinnigan LTQ linear ion-trap mass spectrometer. The data were collected in 
the “triple-play” mode (MS scan, Zoom scan, and MS/MS scan). The acquired data 
were filtered by proprietary software and Database searching against International 
Protein Index (IPI) database. NR-Homo Sapiens database was carried out using both 
SEQUEST and X!Tandem algorithms. Protein quantification was carried out using the 
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LC/MS-based label-free proprietary protein quantification software licensed from Eli 
Lilly and Company [72]. Briefly, once raw files are acquired from the LTQ, all 
extracted ion chromatogram (XIC) is aligned by retention time. Each aligned peak 
should match parent ion, charge state, daughter ions (MS/MS data) and retention time 
(within a one-minute window). If any of these parameters were not matched, the peak 
will be disqualified from the quantification analysis. The area-under-the-curve (AUC) 
from individually aligned peak was measured, normalized, and compared for their 
relative abundance. All peak intensities were transformed to a log2 scale before 
quantile normalization [73]. If multiple peptides have the same protein identification, 
then their quantile normalized log2 intensities were averaged to obtain log2 protein 
intensities. The log2 protein intensity is the final quantity that is fit by a separate 
ANOVA statistical model for each protein. log2 (Intensity) = overall mean + group 
effect (fixed) + sample effect (random) + replicate effect (random). Group effect refers 
to the effect caused by the experimental conditions or treatments being evaluated. 
Sample effect is caused by random effects from individual biological samples. It also 
includes random effects from sample preparation. The replicate effect refers to the 
random effects from replicate injections of the same sample. All of the injections were 
in random order and the instrument was operated by the same operator. The inverse 
log2 of each sample mean was determined to resolve the fold change between samples.  
 
3.1.2 Yeast Grr1 knock-out proteomics method  
     For the yeast Grr1 knock-out study, a customized SILAC approach was used to 
perform mass labeling. S.cerevisiae strain DBY2059 (Mat α leu2-3) was cultured 
overnight to stationary phase in two replicate 10ml batches of modified SD media 
consisting of 2% glucose, .5% glutamine, and .05 mg/ml C6
13 
leucine (Cambridge 
Isotope Laboratories, Inc., Andover, MA, USA). Concurrently, strain JH001 (Mat A, 
grr1Δ::Nat) was also cultured overnight to stationary phase in two replicate 10ml 
batches of the same media supplemented with C6
12 
leucine. Each 10ml culture was 
then used to inoculate a 500ml culture of the same media and cells were grown for 
nine population doublings to mid-log phase (~5x10
6
 cells/ml). Cell density was 
determined by cell counting using a hemacytometer (Reichert, Buffalo,NY, USA.). 
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Cells were harvested by centrifugation in a Beckman JA-14 rotor at 4000 X G for 10 
minutes, washed three times in ice cold water, and immediately re-suspended in 5ml 
of extraction buffer [8M Urea, 0.1M Ammonium Bicarbonate]. Cells were then 
immediately flash frozen in liquid nitrogen and stored at -80C overnight. Protein 
extract was prepared the following day by manual bead beating using 300 um acid 
washed glass beads (Sigma, St.Louis, MO). Specifically, samples were subjected to 10 
cycles consisting of 30 seconds on ice and 30 seconds of vortexing in the presence of 
glass beads. Glass beads and cellular debris were then spun down at 2000 X G and the 
supernatant was placed in 15ml conical tubes. Protein concentrations were determined 
using the Bradford protein assay and protein samples were mixed in a 1:1 ratio 
(DBY2059 C6
13 
leucine: JH001 C6
12 
leucine) producing two replicate protein mixes 
from four independently grown batch cultures. Each protein mixture was diluted with 
100mM Ammonium Bicarbonate to a final Urea concentration of 4M. Protein 
disulfide bond reduction was carried out by adding a 40 fold molar excess of 
Dithiothreitol (DTT) to each protein mixture followed by a three hour incubation at 
36
◦
C. Reduced protein mixtures were then alkylated using a 1:80 molar ratio of protein 
to iodoacetamide (IAM) followed by incubation on ice in complete darkness for 2 
hours. The reduced and alkylated protein mixture was then diluted to 2M Urea using 
an equal volume of 100mM ammonium bicarbonate and subjected to trypsin digestion 
using 2% (weight/weight) of TPCK-treated trypsin. Digestion was carried out at 37
◦
C 
for twenty four hours. Peptide samples were then dried down in a speed-vac and 
resuspended in a buffer consisting of 5% Acetonitrile, 95% EMD water, 0.025% 
Formic Acid, and 0.0025% HFBA. 
 
     The two replicate peptide mixtures were analyzed 3 times each through an 
automated de-salt/2DLC/MS system. Peptide De-salting and separation were 
performed in tandem using the Paradigm MG4 HPLC System (Michrom Biosciences, 
Inc.). Initially, approximately 150ug of the tryptic peptide mixture was loaded directly 
onto a C-18 microtrap (Michrom Biosciences, Inc.) and desalted by flushing the trap 
with 20 column volumes of mobile phase A (2% Acetonitrile, 98% Water, 0.025% 
Formic Acid) at a flow rate of 50 ul/min. Peptides were then eluted onto an SCX 
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microtrap (Michrom Biosciences, Inc.) using 20 volumes of mobile phase B (98% 
Acetonitrile, 2% Water, 0.025% Formic Acid, 0.001% HFBA). Peptides were then 
bumped off the SCX microtrap in a stepwise fashion using increasing concentrations 
of Ammonium Formate. Ten steps were used in our analysis of 0, 4, 8, 12, 15, 18, 21, 
25, 50, and 100 mM Ammonium Formate followed by two identical steps of 1M 
Ammonium Formate. Each population of peptides were eluted off the SCX micro-trap 
onto a C8 nano-trap (Michrom Biosciences, Inc.) coupled directly to a hand packed 
C18 column with a hand pulled tip. A home made high pressure bomb was used to 
pack 15 cm of 5um-100 angstrom Magic C18 resin (Michrom Biosciences, Inc.). 
Peptides were then eluted off this column at 500nl/min using an Acetonitrile gradient 
from 5-50% and analyzed by an LTQ Mass Spectrometer (Thermo Electron 
Corporation) on the fly. 
 
     The LTQ-MS was set for data dependent MS/MS acquisition with a total ion count 
threshold of 1000. Dynamic exclusion was used to only collect two MS/MS spectra on 
a single parent ion every 45 seconds. Two types of data collection were performed in 
this analysis termed gas phase fractionation and full scan analysis. Typically, the 
LTQ-MS is set to scan across an m/z range from 500-2000 throughout the course of 
the analysis. This type of analysis was done in replicate for both replicate peptide 
mixtures culminating in four, 12 step full scan analyses. Each of the peptide mixtures 
was also subjected to a single gas phase fractionation analysis. This analysis is 
essentially equivalent to three full scan analyses but the mass spectrometer is set to 
scan 1/3 of the m/z scan range. This allows for greater m/z resolution and increased 
peptide detection sensitivity due to the fact MS/MS spectra are being collected for a 
smaller fraction of the peptide population eluting from the column. However, this 
process is time consuming given that three separate analyses must be performed to 
acquire data across the whole scan range and thus we only conducted a single gas 
phase analysis for each peptide mixture. The scan ranges for gas phase fractionation 
were 500-1000 m/z, 900-1500 m/z, and 1400-2000 m/z. In all, each of the two 
replicate peptide mixes were loaded and analyzed five times through the 2D-LC-MS 
system for a total of ten different runs.  
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     Peptide assignments for experimental MS/MS spectra were made using the 
SEQUEST program (Thermo Electron Corporation). The 12 raw files generated for 
each run are run individually through the SEQUEST software. Peptide assignments 
were then analyzed for validity using a suite of software available from the Institute 
for Systems Biology termed the Trans-Proteomic Pipeline. This analysis toolkit 
provides computational tools that validate peptide assignments (Peptide Prophet), 
protein assignments (Protein Prophet), and quantify relative peptide and protein 
abundance ratios (ASAPRatio). It is important to note that prior to analysis through 
the TPP the 12 .raw files are combined into a single mzXML using the TPP. This 
mzXML file captures raw parent MS spectra for use in quantification by the program, 
ASAPratio. The SEQUEST output files are converted to summary.html files that are 
readable by the programs Peptide Prophet and Protein Prophet. All the individual .raw 
files and SEQUEST .out files for a given analysis are analyzed together through the 
TPP to calculate the most accurate peptide probabilities, protein probabilities, and 
ratios for a given analysis.  
  
3.2 Preparation of Datasets 
 
3.2.1 Proteins in differentially expressed cisplatin-resistant vs. cisplatin-sensitive 
ovarian cancer cells 
     The protein quantification data was stored in Oracle schema Sysbio (see appendix 
1). 574 differentially expressed proteins with q-value (false discovery rate) <=0.10; 
both up- and down-regulation values or 141 proteins (with q-value <=0.05) were 
generated by mass spectrometry based proteomics experiment. Proteins were mapped 
into IPI database IDs. These IPI identifiers were converted into UniProt IDs in order to 
integrate this data set with all other annotated public data. 119 of the 141 proteins 
(0.05 q-value threshold) were successfully mapped and converted (see appendix 2), 
using the International Protein Index (IPI) database[74] downloaded in February 2006, 
the UniProt database downloaded in November 2005[75], and additional internally 
curated public database mapping tables. Similarly, 451 out of the 574 proteins with the 
less strict threshold (q-value <=0.10) were mapped from IPI IDs to UniProt IDs. 
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3.2.2 Differentially expressed proteins identified from Grr1 knock-out yeast vs. 
wild-type yeast 
     For each protein identified in mass spectrometry experiment, there are two 
measures: (i) the probability that the identification is correct (output from 
ProteinProphet) and (ii) the relative abundance ratio and its standard error (output 
from ASAPratio).  
 
     Since some proteins might be identified by more than one experiment, one can 
improve the reliability and accuracy of the two measures by combining the estimates 
from each experiment. If a protein is identified by k experiments, labeled r1, r2,… rk, 
then the summarized probability is calculated as: 
1
1 (1 )
i
k
id r
i
P P

   , 
Where 
ir
P is the probability measure from experiment
ir .  
 
     To summarize the estimate of the relative abundance ratio, we use a linear 
combination of the estimate at the log10 scale from each experiment. The weight is 
determined so that the summarized estimate has the lowest standard error among all 
possible linear combinations. Then the z-score is calculated by dividing the 
summarized estimate by its standard error for each protein. The local false discovery 
rate approach proposed by Effron[76] is applied to the z-scores to calculate the 
probability that the relative abundance ratio is different from 1 (
ratioP ). Finally, we take 
id ratioP P P  as the final confidence measure that a protein is differentially expressed 
between the two samples. In other words, to be claimed as “differentially expressed”, 
a protein needs to have high confidence in its identification and high confidence in its 
differential abundance. 184 proteins were selected (Combined Probability>=0.8) from 
Grr1 knock-out vs. wild-type yeast mass spectrometry experiment (see appendix 3). 
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3.2.3 Protein interactome data 
     The primary source of human data comes from the Online Predicted Human 
Interaction Database (OPHID) [58], which were downloaded in February 2006. It 
contains more than 47,213 human protein interactions among 10,577 proteins 
identified by UniProt accession numbers. After mapping the proteins in OPHID to 
UniProt IDs, we recorded 46,556 unique protein interactions among 9,959 proteins. 
Note that even though more than half of OPHID entries are interacting protein pairs 
inferred from available lower organisms onto their human orthologous protein pair 
counterparts, the statistical significance of these predicted human interactions was 
confirmed by additional evidences according to OPHID and partially cross-validated 
according to our previous experience [77]. We assigned a heuristic interaction 
confidence score to each protein interaction, based on the type and source protein 
recorded in OPHID according to a method described in [77]. We call this data set PiD0. 
 
49%
12%
39%
BIND ONLY
SGD ONLY
BIND AND SGD
OVERLAPPINGS
 
 
Figure 3.1 Yeast interactome data source from BIND and SGD. The percentages 
show the proportion of the non-redundant interacting pairs of each category among the 
combined non-redundant interacting pairs from BIND and SGD. 
 
     The source of yeast interactome data was the Saccharomyces Genome Database 
(SGD) [58], Biomolecular Interaction Network Database (BIND), and a small set of 
in-house manually curated data by our biology group (Goebl). The data from SGD and 
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BIND were downloaded in February 2006. Figure 3.1 summarized the percentage of 
overlappings of the interactome data from SGD and BIND. A total of 25,418 non-
redundant interactions were obtained after combining the 3 interactome datasets and 
the intensive processing (see Figure 3.2 for the data processing flow chart). We call 
this interactome dataset SBG. Non-redundant interactions are defined as the 
interactions that only contain unique interacting pairs. The same interaction detected 
by different methods or published in different papers is counted as one unique pair. 
For each interacting pair in SBG, we calculated a reliability score based on the scoring 
model developed (see section 3.3). 
 
 
 
Figure 3.2 Interactome data integration flow chart
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3.2.4 Noise-introduced human protein interactome data 
     To test how robust the final computational results would hold up against noise, 
which is commonly believed to exist in large portions of the public protein interaction 
data set, we generated two additional human protein interaction data sets, PiD-a20 and 
PiD-r20.  
 
     For PiD-a20, we add “protein interaction noise” by randomly connecting protein 
pairs from the set of 9,959 unique proteins for as many times as necessary to 
eventually generate 120% * 46,556= 55869 unique interactions. Therefore, we 
generate 20% new and unique “noisy” interactions in the PiD-a20 data set.  
 
     For PiD-r20, we eliminate “protein interaction noise” by randomly removing 
protein interaction pairs from the total 45,556 initial pairs of protein interactions in 
PiD0 to eventually reduce the total number of protein interactions down to (1-20%) * 
46,556= 37,243. Therefore, 80% of original interactions are kept intact in the PiD-r20 
data set. 
 
3.2.5 Gene annotation data  
     The human gene annotation database was downloaded from 
http://www.genmapp.org in January 2006. The whole annotation database (in MS 
Access) was then migrated to Oracle 10g. Human proteome GO annotation was 
performed based on human gene GO annotation and human gene ID to protein 
UniProt ID mappings. 
 
     The yeast gene annotation database was downloaded from www.genmapp.org in 
January 2006.  This database (in MS Access) was migrated to Oracle 10g. We also 
downloaded additional annotation datasets from other websites such as 
http://www.yeastgenome.org in January and February. Based on these datasets, we 
designed and implemented our yeast gene annotation database (see Figure 3.3). Yeast 
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proteome GO annotation was performed based on yeast gene GO annotation and yeast 
gene ID to ORFs mappings curated internally. 
 
 
Figure 3.3 ERD diagram of yeast annotation database stored in Oracle 10g 
 
3.2.6 Interacting protein categorical annotation data 
     Each GO term from the human or yeast protein annotation data was annotated with 
its minimal GO level number in the GO term hierarchy. Each GO term‟s higher-level 
parent GO terms (multiple parent GO terms are possible) up to GO level 1 (three GO 
terms at this level: molecular function, cellular components, and biological processes) 
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are also traced and recorded in an internally curated GO annotation table. When 
calculating interacting protein GO category information, we use this internally curated 
GO term table to map all the low-level GO term IDs (original GO Term ID) used to 
annotate each protein to all the GO term IDs‟ high-level GO term IDs (folded GO 
Term ID). For this study, we designate that all the folded GO term ID should be at GO 
term hierarchy Level = 3. Note that our method allows for multiple GO annotation 
Term IDs (original or folded) generated for each protein ID on purpose. Therefore, it 
is possible for a protein or a protein interaction pair to appear in more than one folded 
GO term category or more than one folded GO term interacting category pairs.  
 
3.3 Protein-Protein Interaction Scoring Model 
     The reliability score of a pair of interaction can be assigned based on what 
experimental methods detected the interaction, how many different methods were used, 
and how many different papers have published the same interaction.  
 
     Our scoring model was developed in 3 steps:  
     First, we mapped the interaction methods stored in SGD (see table 3.1) or BIND 
(see table 3.2) into certain codes: for SGD, the code begins with “s”; for BIND, the 
code begins with “b”. Then we created our metadata (see table 3.3) to unify the 
experimental methods for interacted pairs stored in SGD and BIND. We created the 
code for the unified method, which begins with “G”. For each unified term, a 
reliability score was assigned based on the characteristics of the experimental method. 
Generally, interactions identified from low throughput experiments are more reliable 
than from high throughput experiments, for example, the method “Two Hybrid” was 
assigned the lowest score “0.1”. Based on this, an interaction pair j identified by 
experimental method i can be assigned a base score of S0ji.  
 
(2) For interaction pair j, a specified experimental method i can associate with certain 
number (Cji) of unique PubMed IDs. A maximum number of publications can be 
calculated among all methods for the same pair of interaction. The adjusted rate  ji 
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for experimental method i of a certain interacted pair j can be calculated as (see figure 
3.4): 
 
1
10%
max(max 1,  1)
Cji
ji
Cji


 

 
(Where j denotes the jth unique interaction pair, i denotes the ith experimental method) 
 
     The adjusted score for experimental method i of a specified interaction pair j can be 
calculated as (see figure 3.4): 
S ji = S0ji ( 1+   ji) 
 
 
Figure 3.4 Protein interaction reliability score calculation algorithm and 
formulas. PMID stands for PubMed ID. 
 
(3) Similar to  [78], we combine Sj1, Sj2, …, Sji, …, Sjn  and calculate a final score Sj 
for the specified interaction pair j (see figure 3.4). 
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Table 3.1 Experimental methods for interacting pairs stored in SGD. 
SGD Method Code SGD Method 
s1 Affinity Capture-MS 
s2 Affinity Chromatography 
s3 Affinity Precipitation 
s4 Biochemical Assay 
s5 Dosage Lethality 
s6 e-map 
s7 Purified Complex 
s8 Reconstituted Complex 
s9 Synthetic Growth Defect 
s10 Synthetic Lethality 
s11 Synthetic Rescue 
s12 Two-hybrid 
 
Table 3.2 Experimental methods for interacting pairs stored in BIND. 
BIND Method Code BIND Method 
b1  (Blank) 
b2 affinity-chromatography 
b3 autoradiography 
b4 colocalization 
b5 competition-binding 
b6 cross-linking 
b7 deuterium-hydrogen-exchange 
b8 electron-microscopy 
b9 electron-spin-resonance 
b10 elisa 
b11 equilibrium-dialysis 
b12 far-western 
b13 fluorescence-anisotropy 
b14 footprinting 
b15 gel-filtration-chromatography 
b16 gel-retardation-assays 
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b17 hybridization 
b18 immunoblotting 
b19 immunoprecipitation 
b20 immunostaining 
b21 interaction-adhesion-assay 
b22 light-scattering 
b23 mass-spectrometry 
b24 membrane-filtration 
b25 monoclonal-antibody-blockade 
b26 not-specified 
b27 other 
b28 phage-display 
b29 resonance-energy-transfer 
b30 sucrose-gradient-sedimentation 
b31 surface-plasmon-resonance-chip 
b32 three-dimensional-structure 
b33 transient-coexpression 
b34 two-hybrid-test 
 
Table 3.3 Metadata for experimental methods 
SGD and BIND 
Method Code 
Code Unified Term Reliability Score 
b2, s1, s2, s3, b19 G1 Affinity_Purification 0.8 
b6 G2 Cross_Linking 0.5 
b10 G3 Elisa 0.7 
b28 G4 Phage_Display 0.1 
b29 G5 Resonance_Energy_Transfer 0.4 
b34, s12 G6 Two_Hybrid 0.1 
s6 G7 E_Map 0.8 
s9, s10 G8 Synthetic_Growth_Defect 0.8 
s11 G9 Synthetic_Rescue 0.8 
s7 G10 Purified_Complex 0.8 
s5 G11 Dosage_Lethality 0.8 
s4 G12 Biochemical_Assay 0.8 
s8 G13 Reconstituted_Complex 0.6 
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b3, b4 ~ b9 G99 Other 0.1 
b11, b12 ~ b18 G99 Other 0.1 
b20, b21 ~ b27 G99 Other 0.1 
b1, b30 ~ b33 G99 Other 0.1 
 
3.4 Network Expansion 
     We derive differentially expressed protein interaction sub-network using a nearest-
neighbor expansion method described in [77]. We call the original list of differentially 
expressed proteins (119 proteins in ovarian cancer study or 184 proteins in yeast Grr1 
knock-out study) seed (S) proteins and all the protein interactions within the seed 
interactions (or S-S type interactions). After expansion, we call the collection of seed 
proteins and expanded non-seed (N) proteins sub-network proteins (including both S 
and N proteins); we call the collection of seed interactions and expanded seed-to-non-
seed interactions (or S-N type interactions) sub-network protein interactions (including 
both S-S type and S-N type interactions). Note that we do not include non-seed-to-
non-seed protein interactions (or “N-N” type interactions) in our definition of the sub-
network, primarily because the N-N type of protein interactions often outnumbered 
total S-S and S-N types of protein interaction by several folds with molecular network 
context often not tightly related to the initial seed proteins and seed interactions. The 
only occasion to consider the N-N type interactions is when we calculate sub-network 
properties such as node degrees for proteins in the sub-network. 
 
3.5 Network Visualization 
 
     We use Spotfire DecisionSite Browser 7.2 to implement the 2-dimensional 
functional categorical crosstalk matrix for human ovarian cancer drug resistance study. 
To perform interaction network visualization, we used ProteoLens[79]. ProteoLens 
has native built-in support for relational database access and manipulations. It allows 
expert users to browse database schemas and tables, query relational data using SQL, 
and customize data fields to be visualized as graphical annotations in the visualized 
network.  
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3.6 Network Statistical Examination 
     Since the seed proteins are those that are found to display different abundance level 
between two different cell lines via mass spectrometry, one would expect that the 
network  “induced” by them to be more “connected” in the sense that they are to a 
certain extent related to the same biological process(es). To gauge network 
“connectivity”, we introduced several basic concepts. We define a path between two 
proteins A and B as a set of proteins P1, P2,…, Pn such that A interacts with P1, P1 
interacts with P2, …, and Pn interacts with B. Note that if A directly interacts with B, 
then the path is the empty set. We define the largest connected component of a 
network, as the largest subset of proteins such that there is at least one path between 
any pair of proteins in the network. We define the index of aggregation of a network 
as the ratio of the size of the largest connected component of the network to the size of 
the network by protein counts. Therefore, the higher the index of aggregation, the 
more “connected” the network should be. Lastly, we define the index of expansion of 
a sub-network as the ratio of S-S type interactions among seed proteins over all seed 
and expanded sub-network interactions (S-S and S-N types). The higher the index of 
expansion, the more relevant roles seed proteins plays in the network.  
 
     To examine the statistical significance of observed index of aggregation and index 
of expansion in expanded protein networks, we measure the likelihood of the topology 
of the observed sub-network under random selection of seed proteins. This is done by 
randomly selecting 119 proteins (in ovarian cancer study) or 184 proteins (in yeast 
Grr1 knock-out study), identifying the sub-network induced/expanded, and calculating 
sub-network indexes accordingly. The same procedure is repeated n=1000 times to 
generate the distribution of the indexes under random sampling, with which the 
observed values are compared to obtain significance levels (for details, refer to [77]). 
3.7 Significance of Testing of GO Categories and GO-GO Categories 
     To assess how significantly the seed proteins (119 in human study and 184 in yeast 
study) in the subnetwork are distributed across their specific GO function categories, 
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we hypothesize the task as observing the outcome of a random draw of the same 
number of proteins from the pool of proteins in the whole interacting network (9959 
proteins in human study and 5240 in yeast study). Then the count in a certain GO 
category follows a hypergeometric distribution. A p-value is calculated based on the 
hypergeometric distribution to evaluate the likelihood that we observe an outcome 
under random selection of a subset of proteins (119 in human and 184 in yeast) that is 
at least as “extreme” as what we have observed. Note “extreme” either implies an 
unusually large (over-representation) or usually small (under- representation) number. 
Let x be the count of the seed proteins that falls in a function category in the 
subnetwork, n is the sample size (119 in human study, or 184 in yeast study), N is the 
population size (9,959 in human study, or 5240 in yeast study), and k=corresponding 
count in OPHID, then the p-value for over/under-representation of the observed count 
can be calculated as:  
 
Over representation: 
 
Under representation:   
       
     We also expand the protein list from the 184 seed proteins to 1251 sub-network 
proteins in yeast study, and calculate a p-value for randomly drawing of 1251 proteins 
from the pool of 5240 proteins in SBG based on its hypergeometric distribution. 
 
     Similarly, we can use the above formula to assess how significantly the protein 
interactions from the seeded subnetwork are distributed across specific GO-GO 
functional interaction categories. For a GO-GO functional interaction category, we 
refer to a pair of GO categories, which are derived by aggregating all the protein-
protein interaction pairs with the same pairing of GO annotation categories for the 
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interacting proteins. For example, if 3 protein interactions share annotation category A 
in one side of the interaction, and annotation category B in the other side of the 
interaction, we say that A-B is a functional interaction category with an observed 
count of 3. To identify significant GO-GO functional interaction category in the 
seeded subnetwork, we hypothesize the task as the observing the outcome of a random 
draw of 1,723 pairs from the pool of 46,556 pairs in OPHID in human study (or 
random draw of .1,698 pairs from the pool of 25,418 pairs in SBG in yeast study). 
Then the count of a certain GO-GO function interaction category follows a 
hypergeometric distribution. A p-value for over/under-representation of the observed 
count can be calculated similarly, based on the hypergeometric distribution. Since tests 
of over/under representation of various categories are correlated with one another 
(over representation of one category could imply under representation of other 
categories), we also control the false discovery rate (FDR) using method developed by 
Benjamini and Yekutieli.[80]  
3.8 Validation of Under-Represented GO Categories 
 
      
Figure 3.5 Illustration showing the overlap of 9959 OPHID proteins and 4333 
proteins detected by MS experiments. 119 seed proteins is a high-confidence subset 
of the overlapped proteins. 
 
     Proteomics techniques are generally known for problems with false positives and 
false negatives, primarily for reasons such as complex digested peptide samples, noisy 
un-separated peptide peaks, and computationally intensive protein/peptide 
9,959 OPHID proteins
3,690 proteins in both 
OPHID and MS
4,333 proteins detected 
by MS
119 
seed 
proteins
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identifications that cannot afford to take all post-translational modifications into 
account. Since we control false positives by choosing 119 high-confidence seed 
proteins in this study, false negatives, instead of false positives, are a potential concern. 
Therefore, when we interpret over-/under- representation of proteins in GO functional 
categories or GO-GO functional interaction categories, over-representation results are 
likely under-exaggerated and will remain true, but under-representation results are 
likely over-exaggerated and needs additional validation or some adjustment. 
 
     We take 4,333 of all reported proteins, which includes proteins identified with both 
high and low confidence, from the MS search software, and overlap this set with all 
the 9,959 proteins found in OPHID. Out of 4,333 raw UniProt IDs, 3,690 of which can 
be further mapped to OPHID interaction human database. The 3,690 is then assumed 
to be the upper limit of instrument/software detectable proteins. When re-examining 
over-/under- representation GO functional categories, we let n=3,690, N=9,959, 
k=corresponding count in OPHID, and use the same formula introduced in section 2.6 
to calculate significant protein  over/under- representation. This relationship is 
illustrated in Figure 3.5. 
3.9 Drill-Down of Significant Categories 
     Once certain GO functional categories or GO-GO functional interaction categories 
are determined to be significant, they become candidates for subsequent “drill-down” 
examinations. For drill-down of GO functional categories, we refer to exploration of 
the next-level GO functional annotation by tracing down the GO structure and re-
calculating the significance value, based on each protein‟s new next-level GO 
functional annotation labels, using methods described in section 2.6. For drill-down of 
GO-GO functional categories, we refer to exploring the next-level GO-GO functional 
annotations by tracing both proteins of the interaction pair down the GO structure and 
re-calculating the significance value. The new next-level GO-GO functional 
annotation categories consist of all paired combinations of sub GO functional 
categories. The use of drill-down allows us to zoom in our attention to detailed 
biologically interesting categories to obtain further insights in enriched molecular 
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functions and biological processes without incurring a huge computational cost at the 
very beginning of the exploration. 
3.10 Scoring of Significant Proteins in the Sub-Network 
     Protein ranking analysis was performed in MS Access front-end database which 
connects to the Oracle back-end database. First, 184 differentially expressed proteins 
were imported (with replacement) into linked Oracle table from the application 
interface (see Figure 3.6 ) after correct login information was verified, then the 
application automatically create the sub-network data by querying the linked Oracle 
SBG interactome dataset. We calculated ranking scores for the significant proteins in 
the sub-network using the heuristic relevance scoring formula[81]: 
 
1
2* ( ) ( )
i
i
k
i ij
j
R LOG S LOG k

   
Where Ri is the ith seed protein ranking score, Ki denotes its connectivity, and Sij 
denotes its interaction reliability score with the jth partner. 
 
 
Figure 3.6 Application for the yeast subnet construction 
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      Our ranking analysis was built on the hypothesis: the significance of a protein‟s 
contribution in the network depends on its ability to connect to other proteins in the 
network and the reliability of the detected interactions. The higher the connectivity 
and reliability, the higher the ranking score should be.  
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4. RESULTS 
 
Case Study 1. Ovarian Cancer Drug Resistance Case Study 
 
     This part was written based on the published result[2], where I am one of the 
primary contributing members. The use of the material was granted with the 
permission from participating contributors. 
4.1 Activated Protein Interaction Sub-Network Properties 
     The network topology for the protein interaction sub-network expanded from seed 
proteins was examined. The resulting protein interaction sub-network (core sub-
network) consists of 1,230 seed and non-seed proteins in 1,723 sub-network 
interactions (including 17 S-S type interactions and 1,706 S-N type protein 
interactions). The node degree frequency distributions were plotted in Figure 4.1, 
where the whole human protein interaction network from OPHID (labeled “network”) 
is also shown. As expected, both the network and the sub-network (full) display good 
“scale-free” property. These results also show that the cisplatin resistant activated sub-
network (full) contains more “hubs” than “peripheral” proteins to form a cohesive 
functional sub-network. The core sub-network, while perhaps limited in size, shows 
“scale-free like” distribution, although hubs in the sub-network (core) are more 
distinctively identifiable than overly abundant peripheral nodes by high node degree 
counts.  
 
     Other network features for the core sub-network are also examined. The largest 
connected component (defined in the Method section; ibid) of the sub-network 
consists of 1193 proteins. The index of aggregation is 1193/1230=97.0%. The index of 
expansion as the percentage of S-S type interactions (17) over the core sub-network 
interactions (1723), i.e., 17/1723=0.96%. The index of aggregation has a p-value of 
less than 0.001 (upper tail) and the index of expansion is 0.06 (upper tail) A significant 
and high network index of aggregation suggests that the core sub-network has 
connectivity structures that are not random by nature. This correlates well with the 
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node degree distribution in Figure 4.1, where an exceptionally large number of hubs 
are shown to exist.  
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Figure 4.1 Node degree distribution of the sub-networks (core or full) in 
comparison with the human protein interaction network. 
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4.2 Analysis of Activated Protein Functional Category Distributions 
     Although GO-based functional category analysis can be done routinely using many 
existing bioinformatics methods [3], the inclusion of protein interaction network 
context has not been previously described. In this analysis, we are more interested in 
enriched protein categories in the cisplatin-response functional process. This includes 
both up-regulated and down-regulated proteins. Therefore, we transformed protein-
protein interaction sub-network to GO cross-talk sub-network. Enriched protein 
functional categories were discovered among differentially expressed seed proteins 
and its immediate protein interaction sub-network nearest interaction partners.  
 
     Table 4.1 shows significantly enriched GO categories in the sub-network. 17 GO 
categories were filtered from 70 GO categories (data not shown). The filter criteria are 
1) the P-value over- or under- representation must be within 0.05 and 2) the total 
category count of GO in the whole network is greater than 10. In GO_TERM column, 
we have listed three types of information: level 3 GO terms, GO term category type 
(„C‟ for cellular component, „F‟ for molecular function, and „P‟ for biological process; 
in parenthesis preceding the dash), and GO identifier (seven digit number following 
the dash in parenthesis). In the ENRICHMENT column, we listed two types of 
counts of proteins with GO annotation levels falling in the corresponding category: 
within core sub-network and whole network (in parenthesis). In the PVALUE column, 
we have listed two numbers: the p-value from the significance test of whether there is 
an over- or an under- representation (two numbers separated by a „/‟) of an observed 
GO term category count in the sub-network. In the last CONCLUSION column, „++‟ 
suggests significant over-representation when the false discovery rate (FDR) is 
controlled at 0.05, „--‟ suggests significant under-representation when FDR controlled 
at 0.05, „+‟ to suggest insignificant over-representation when FDR controlled at 0.05 
but significant overrepresentation at native p-value=0.05, „-‟ to suggest insignificant 
over-representation when FDR controlled at 0.05 but significant overrepresentation at 
native p-value=0.05.  
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Table 4.1 Enriched GO categories in the sub-network Context. An asterisk 
indicates adjustment may be needed for further interpretation. 
 
     We also tested how robust the network is by introducing noise in protein 
interaction data sets. Two experiments were performed (for a description of the 
methods, see section 3.1.1) : “add20”, in which we added 20% new randomly-selected 
GO_TERM ENRICHMENT 
PVALULE 
(OVER/UNDER) CONCLUSION 
membrane (C-0016020)*       7 (2034)     1/0          -- 
proton-transporting two-sector 
ATPase complex (C-0016469)  2 (12)     .009/1      + 
non-membrane-bound 
organelle (C-0043228)           19 (834)     .005/.9980  + 
organelle lumen (C-0043233)                                2 (13)     .0101/.9996  + 
proton-transporting ATP 
synthase complex (C-0045259)                                         2 (17)     .0171/.9990  + 
proton-transporting ATP 
synthase complex\, catalytic 
core (C-0045261)                                       1 (1)  0.012/1          + 
proton-transporting ATP 
synthase, catalytic core  
(C-0045267) 1 (1) 0.012/1 + 
protein binding (F-0005515)                                26 (1387) .012/.9937  + 
drug binding (F-0008144)                                   2 (12)     0.009/1  + 
isomerase activity (F-0016853)                             7 (69)     0/1  ++ 
nucleotide binding (F-0000166)                           23 (1205)    .0148/.9923 + 
receptor activity (F-0004872)*                               2 (642)    .9968/.0149  - 
receptor binding (F-0005102)*                               1 (422)    .9944/.0354  - 
oxidoreductase activity  
(F-0016491) 12 (271) 0/1 ++ 
                           Kinase 
regulator activity (F-0019207) 3 (50) 0.022/0.9970 + 
metabolism (P-0008152) 67 (4634) 0.020/0.9875 + 
response to biotic stimulus  
(P-0009607)*  1 (711) 1/0.0014 - 
regulation of physiological 
process (P-0050791)*                 17 (2129)  .9817/.0328  - 
regulation of cellular process 
(P-0050794)*                             15 (2182)  .9968/.0066  - 
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connections between OPHID proteins to create a new OPHID proteins data set PiD-
a20, and “remove20”, in which we removed 20% existing randomly-selected 
connections between OPHID proteins to create a new OPHID proteins data set PiD-
r20. Surprisingly, although the individual category counts fluctuate, all conclusions 
made through the above-described threshold values of p-value and FDR remain the 
same (this conclusion also remains true for high-level GO-GO category enrichment 
experiments in next section; results not shown). This suggests the significance of our 
discovery is robust against reasonable noise inherent in the protein interaction 
databases. 
 
     After the above analysis, we then re-examined all “under-represented categories” 
under a new false-negative controlled experiment to see if these under-representations 
have been “exaggerated” due to bias of the MS experimental methods. Therefore, we 
set up an experiment to observe the inherent bias (either over- or under- representation) 
in all detectable MS proteins overlapped with OPHID data sets (also described in 
section 3.1.6).  
 
Table 4.2 Re-examination of under-represented seed protein functional 
categories 
 
GO_TERM 
P-VALUE, OVER-
REPRESENTED 
(seed/background) 
P-VALUE, 
UNDER-
REPRESENTED 
(seed/background) 
CONCLU-
SION 
Membrane (C-0016020)       1.0000 (.00000) .00001 (1.0000) -- 
receptor activity (F-0004872)                               .99681 (.00002) .01489 (.99998) -- 
receptor binding (F-0005102)                               .99439 (.99937) .03550 (.00092) ? 
response to biotic stimulus  
(P-0009607)  .99986 (1.0000) .00144 (.00000) ? 
regulation of physiological 
process  
(P-0050791)                 .98169 (.00000) .03276 (1.0000) -- 
regulation of cellular process 
 (P-0050794)                             .99685 (.00000) .00664 (1.0000) -- 
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     Table 4.2 lists the results. Here seed experiment refers to the earlier experiment 
which we examined the enrichment (in this case, all under-representations) of 119 
seed proteins; background experiment refers to the re-examination experiment which 
we examined the enrichment bias of 3690 MS detectable proteins also found in 
OPHID data set. When we observe significant over-representation of certain GO 
functional categories in the background, we make the conclusion that the category is 
indeed under-represented in the seed (marked as “--“).When we observe significant 
under-representation of certain GO functional categories in the background, we make 
the conclusion that the category is not necessarily under-represented (or likely over-
represented) in the seed (marked as “?“ for inclusive). 
 
     From the above comprehensive analysis, we can obtain the following biological 
insights. First, proton-transporting ATP synthase activity is related to the cell cisplatin 
resistance function (see table 5 for the enriched GO categories), which may imply 
higher oxidative energy production capability among cancerous functions in cisplatin 
resistant cell lines over cisplatin sensitive cell lines. This is consistent with the existing 
findings: mitochondria -- “ATP factory”, was considered to be a major target of 
cisplatin, leading to mitochondrial loss of energy production[82]. Second, although the 
protein interaction network in general is inherently enriched with proteins with 
“protein binding” capabilities (note 1412 proteins in the category from the whole 
network), the cisplatin-resistant cell line demonstrated an unusually high level of 
protein-binding activities; in addition, a broad spectrum of across-the-board drug-
binding and nucleotide-binding mechanisms are all activated to fight again cisplatin-
induced DNA damage in cancer cells. This suggests that many intracellular signaling 
cascades are intensely mobilized with cisplatin-resistance. Third, the data suggest that 
the location of the biological activities of cisplatin resistant response take place in 
cytoplasm or nucleus, rather than on “membrane”. This correlates well with the 
previous hypothesis that transporters that are responsible for assisting with cisplatin 
import into the cell seem to become blocked in drug-resistant cells. This analysis gives 
essential clues to the overall picture of molecular signaling events for cisplatin 
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GOT2
cell communication
cellular physiological process
localization
locomotory behavior
metabolism
organ development
organismal physiological process
regulation of cellular process
regulation of development
regulation of physiological process
regulation of viral life cycle
response to abiotic stimulus
response to biotic stimulus
response to endogenous stimulus
response to external stimulus
response to stress
resistant cell lines. We also obtained categorical enrichment data at lower GO levels 
than are shown in this section, using the drill-down method (for method, refer to 
section 3.1.7; results not shown), to obtain detailed views of biological process, 
molecular function, and cellular components.  
4.3 Functional Category Cross-Talks 
     We developed a two-dimensional visualization matrix (extended from our 
technique described in [83]) to show significant cross-talk between GO categories in  
Figure 4.2 (only biological processes at level=3 are shown due to space constraints). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Significantly over-represented GO-GO interaction categories in seeded 
subnetwork. (only biological processes at level=3 are shown due to space constraints).  
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Table 4.3 Drill down of significant GO-GO functional category cross-talk. 
“Cellular Physiological Process” vs. “Cellular Physiological Process” at GO term level 
4. Note only p-value <0.05 for over-representation are shown (FDR<0.05 cases are 
also in bold) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  
GO TERM #1 GO TERM #2 ENRICHMENT 
P-
VALUE  
cell homeostasis (P-
0019725) transport (P-0006810) 18 (120) 0 
transport (P-0006810) transport (P-0006810) 75 (1377) 0.0006 
regulation of cellular 
physiological process (P-
0051244) transport (P-0006810) 130 (2045) 0 
cell cycle (P-0007049) transport (P-0006810) 68 (708) 0 
cell death (P-0008219) transport (P-0006810) 45 (694) 0.0002 
cell proliferation (P-
0008283) transport (P-0006810) 22 (238) 0.0001 
cellular metabolism (P-
0044237) transport (P-0006810) 359 (6041) 0 
cellular metabolism (P-
0044237) cell cycle (P-0007049) 253 (4439) 0 
cellular metabolism (P-
0044237) 
cell proliferation (P-
0008283) 85 (1412) 0 
cell homeostasis (P-
0019725) 
cell organization and 
biogenesis  
(P-0016043) 11 (73) 0.0001 
cellular metabolism (P-
0044237) 
cell homeostasis (P-
0019725) 25 (279) 0 
cellular metabolism (P-
0044237) 
cellular metabolism (P-
0044237) 764 (17604) 0 
cell homeostasis (P-
0019725) cell cycle (P-0007049) 5 (43) 0.0207 
regulation of cellular 
physiological process (P-
0051244) cell cycle (P-0007049) 130 (2655) 0.0007 
cell cycle (P-0007049) cell cycle (P-0007049) 39 (702) 0.0084 
cell organization and 
biogenesis  
(P-0016043) cell cycle (P-0007049) 53 (936) 0.0017 
cell homeostasis (P-
0019725) 
chromosome 
segregation  
(P-0007059) 1 (1) 0.037 
regulation of cellular 
physiological process (P-
0051244) 
cell homeostasis (P-
0019725) 13 (149) 0.0037 
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The size of each node is inversely proportional to the p-value of interacting categories. 
The color legends are: red (dark) for interacting categories that are significant when 
FDR controlled at 0.05; and gray (light) for interacting categories that are not 
significant when FDR controlled at 0.05. The figure 4.2 reveals additional interesting 
findings. First, cellular physiological processes are significantly activated in drug-
resistant cell lines (the largest and reddest dot, at the bottom left corner). This could 
lead to further drill-down of protein interaction in the interacting category for 
biological validations (see Table 4.3 for an example). Second, these cellular 
physiological processes seem to be quite selective rather than comprehensive. For 
example, when looking at significant regulation of cellular response categories, 
significant cross-talk functional patterns strongly suggest the cellular and 
physiological responses arise from endogenous, abiotic, and stress-related signals 
(internalized cisplatin causing DNA damage and inducing cell stress). Using a cross-
talk matrix such as this, cancer biologists can quickly filter out other insignificant 
secondary responses (such as cell growth, cell development shown) to establish a new 
prioritized hypothesis to test. 
4.4 Visualization of the Activated Interaction Functional Sub-Network 
     In Figure 4.3, we show a visualization of the activated biological process functional 
network, using a recently developed software tool “ProteoLens”[79]. ProteoLens is a 
biological network data mining and annotation platform, which supports standard 
GML files and relational data in the Oracle Database Management System (for 
additional details, visit http://bio.informatics.iupui.edu/proteolens/). In the figure 4.3, 
in contrast with regular protein interaction network, we encode nodes as significantly 
over-/under- represented protein functional categories, and edges as significantly 
interacting protein functional categories. Several additional information types are also 
represented. The original abundance (by count) of each functional category is encoded 
in the node size. The p-values of activated protein category significance in the sub-
network is encode as node color intensity, on a scale from light yellow (less significant) 
to dark red (more significant). 
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Figure 4.3 Activated biological process network in cisplatin-resistant ovarian 
cancer cells. Red-colored lines stand for “significant”, while blue-colored lines stand 
for “not significant” (FDR=0.05) 
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     From this figure 4.3 we can see that cisplatin-resistant ovarian cancer cells 
demonstrated significant cellular physiological changes, which are related to cancer 
cell‟s native response to stimulus that is endogenous, abiotic, and stress-related. 
Interestingly, we also observed that the regulation of viral life cycle also plays very 
significant roles in the entire drug resistant process. This previously unknown 
observation may be further examined at protein levels to formulate hypothesis about 
acquired cisplatin resistance in ovarian cancer.  
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Case Study 2. Yeast Grr1 Knock-Out Case Study 
 
     Case study 2 is the collaborative work among the biology group (Dr. Goebl and 
Josh), biostatistics group (Dr. Shen), and Informatics group (Dr. Chen and I).  The 
manuscript is in preparation. 
4.5 Activated Protein Interaction Sub-Network Properties 
 
Figure 4.4  Node degree distribution of the sub-networks (core or full) in 
comparison with the yeast protein interaction network. 
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     The resulting protein interaction sub-network consists of 1,251 seed and non-seed 
proteins in 1,698 sub-network interactions (including 54 S-S type interactions and 
1,644 S-N type protein interactions). This protein interaction sub-network is called a 
“core sub-network”. The “full sub-network” includes all N-N type protein interactions 
in addition to the S-S type and S-N type interactions. We plot their node degree 
frequency distributions in Figure 4.4, where the whole yeast protein interaction 
network from SBG (labeled “network”) is also shown. As expected, both the network 
and the sub-network (full) display good “scale-free” property (some nodes act as 
"highly connected hubs", although most nodes are of low degree). The core sub-
network, while perhaps limited in size, begins to show “scale-free like” distribution, 
although hubs in the sub-network (core) are more distinctively identifiable than overly 
abundant peripheral nodes by high node degree counts.  
 
     We also examined other network features for the core sub-network. The largest 
connected component of the sub-network consists of 1163 proteins with 1637 
interactions. The index of aggregation is 1163/1251=93.0%. The index of expansion 
as the percentage of S-S type interactions (54) over the core sub-network interactions 
(1698) is 54/1698=3.18%. The high network index of aggregation here suggests that 
the core sub-network has high connectivity.  
 
4.6 Analysis of Activated Protein Functional Category Distributions 
 
     We first analyzed significantly enriched GO categories among 184 seed proteins. 
We limited our analysis to level 3 GO categories as previously described. Our result 
revealed 11 significantly enriched GO biological process, functional categories, and 
cellular components in response to Grr1 perturbation. After filtering out the general 
GO categories that have more than 200 ORFs from the whole yeast PPI have been 
annotated to, only 3 significantly enriched GO categories are left (see table 4.4). The 
table column header definition is the same as previously defined in the human case 
study. 
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Table 4.4. Over/under – represented GO categories among the seed proteins 
GO_TERM ENRICHMENT 
(OVER/UNDER
) 
CONCLUSIO
N 
eukaryotic 43S preinitiation 
complex (C-0016282) 5 (55) 0.0427/0.988 + 
lipid transporter activity (F-
0005319) 2 (8) 0.0299/0.9979 + 
oxidoreductase activity (F-
0016491) 16 (184) 0.0007/0.9998 + 
 
 
     The analysis result from the above apparently provides limited information. Thus, a 
simple ontology-based annotation for global proteomics data offers no significant 
further understanding of Grr1 function. This is partially due to the fact that the current 
proteomics techniques are not sensitive enough to capture the whole proteome, 
especially those proteins with low-abundance, e.g. Grr1. However, we expect to find 
many abundant proteins whose expression levels are directly or indirectly regulated by 
Grr1. These proteins may look disparate or isolated in their GO-annotation, but may 
interact with other proteins and impact the cellular components or functions.  
 
     We expanded our protein list by mapping our differentially expressed proteins onto 
protein interaction networks and including the immediate partners in our analysis. The 
expanded sub-network included 1251 proteins (184 seeds and 1067 immediate 
partners). We then mapped these proteins into GO categories and re-analyzed the 
enriched GO categories using statistical methods previously described. We discovered 
53 enriched GO categories including both over- and under-represented GO categories. 
We applied the same filtering criteria to the 53 GO categories to remove generalized 
GO categories that contain 200 or more annotations, and obtained 40 enriched GO 
categories with 15 terms categorized as component terms, 15 categorized as process 
terms, and 10 categorized as function terms (see table 10). The table column header 
definition is the same as previously defined in the human case study. Therefore, the 
application of the GO analysis to the sub-network leads to the extraction of more GO 
terms overall and more specific GO terms. 
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Table 4.5. Over/under – represented GO categories among the subnet proteins 
GO_TERM 
ENRICH-
MENT (OVER/UNDER) 
CONCLU
-SION 
transcription export complex (C-0000346) 4 (4) 0.0032/1 + 
proteasome complex (sensu Eukaryota) (C-
0000502) 25 (37) 0/1 ++ 
transcription factor complex (C-0005667) 43 (106) 0.0001/1 ++ 
mitochondrial inner membrane presequence 
translocase complex (C-0005744) 3 (4) 0.0446/0.9968 + 
proteasome regulatory particle (sensu 
Eukaryota) (C-0005838) 8 (9) 0.0001/1 ++ 
microtubule associated complex (C-0005875) 14 (29) 0.0035/0.999 + 
bud (C-0005933) 48 (107) 0/1 ++ 
eukaryotic 43S preinitiation complex (C-
0016282) 19 (55) 0.0479/0.975 + 
chromatin remodeling complex (C-0016585) 30 (71) 0.0004/0.9998 ++ 
DNA-directed RNA polymerase II\, 
holoenzyme (C-0016591) 32 (66) 0/1 ++ 
external encapsulating structure (C-0030312) 14 (102) 0.9964/0.0077 - 
site of polarized growth (C-0030427) 50 (109) 0/1 ++ 
replisome (C-0030894) 12 (27) 0.0149/0.995 + 
cell projection (C-0042995) 19 (36) 0.0002/1 ++ 
pyruvate dehydrogenase complex (C-
0045254) 3 (4) 0.0446/0.9968 + 
RNA polymerase II transcription factor 
activity (F-0003702) 42 (93) 0/1 ++ 
receptor signaling protein activity (F-
0005057) 8 (13) 0.0041/0.9993 + 
amine transporter activity (F-0005275) 1 (33) 0.9999/0.0014 - 
organic acid transporter activity (F-0005342) 2 (39) 0.9997/0.002 - 
carrier activity (F-0005386) 24 (158) 0.9976/0.0046 - 
enzyme activator activity (F-0008047) 20 (56) 0.0304/0.9848 + 
lipid binding (F-0008289) 11 (15) 0.0001/1 ++ 
protein transporter activity (F-0008565) 11 (25) 0.0211/0.9928 + 
carbohydrate transporter activity (F-0015144) 3 (31) 0.9882/0.041 - 
GTPase regulator activity (F-0030695) 26 (63) 0.0016/0.9994 ++ 
aging (P-0007568) 15 (29) 0.001/0.9997 ++ 
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morphogenesis (P-0009653) 46 (103) 0/1 ++ 
response to endogenous stimulus (P-0009719) 64 (172) 0/1 ++ 
cell growth (P-0016049) 3 (4) 0.0446/0.9968 + 
death (P-0016265) 15 (39) 0.0295/0.9871 + 
sexual reproduction (P-0019953) 41 (93) 0/1 ++ 
asexual reproduction (P-0019954) 39 (75) 0/1 ++ 
cell differentiation (P-0030154) 39 (100) 0.0005/0.9998 ++ 
Filamentous growth (P-0030447) 23 (54) 0.0018/0.9993 ++ 
regulation of growth (P-0040008) 3 (3) 0.0136/1 + 
regulation of gene expression, epigenetic (P-
0040029) 25 (76) 0.0459/0.9737 + 
negative regulation of biological process (P-
0048519) 53 (155) 0.0021/0.9988 ++ 
non-developmental growth (P-0048590) 14 (28) 0.0023/0.9994 ++ 
regulation of enzyme activity (P-0050790) 13 (25) 0.0021/0.9995 ++ 
reproductive physiological process (P-
0050876) 27 (65) 0.0012/0.9995 ++ 
 
     To assess the validity of our analysis, we first determined whether the expanded 
GO annotation was supported by known Grr1 functions from previous publications.  
 
     Grr1 affects many different cellular processes in Saccharomyces cerevisiae through 
its role as a receptor for the SCF ubiquitin ligase[84-86]. In conjugation with this 
multimeric protein complex, Grr1 serves to target protein substrates for ubiquitylation, 
an event that ultimately results in the substrates degradation by the 26S proteasome. 
Currently, there are ten proteins that are thought to be ubiquitylated by the SCF
Grr1
 
ubiquitin ligase, each of these proteins playing distinct roles in multiple cellular 
processes.[86] The cells lacking Grr1 exhibit multiple abnormalities including cell 
elongation, slow growth on glucose, increased sensitivity to osmotic stress and 
nitrogen starvation, decreased divalent cation transport, enhanced filamentous growth, 
defects in sporulation, and slow growth or invariability when combined with amino 
acid biosynthesis mutants.[84, 87-90] We expect our ontology-driven network enabled 
approach would capture some of the GO functions through extracting the enriched GO 
terms directly associated with Grr1 or with the targets of Grr1.    
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     Intriguingly, among the 40 enriched GO categories, 14 GO categories are directly 
ascribed to Grr1 or at least one of its targets, 10 categories over-represented and 4 
under-represented. In figure 4.5, the 10 over-represented GO categories that are 
directly related to Grr1 or related to targets of Grr1 are shown. The Grr1 protein is 
known to participate in regulating bud emergence and growth through its role in 
targeting the Cdc42 effectors Gic1 and Gic2 as well as the cyclins Cln1 and Cln2 for 
degradation by the 26S proteasome [85, 90-93]. The GO categories “polarized 
growth”, “bud”, “morphogenesis”, “asexual reproduction”, and “cell projection” are 
all involved in the elongated bud morphological phenotype of Grr1 knock-out cells. 
The elongated bud morphology resembles invasive growth for Grr1 knock-out yeast. 
Therefore, based on the existing evidence from previous publications, the ontology-
driven network-enabled analysis approach proves to be not only valid, but also have 
the potential to drive the generation of the novel hypothesis for future investigations.   
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Figure 4.5 Enriched GO categories (partial listing) and yeast bud morphological 
phenotype. This figure was modified based on Josh‟s original figure. 
 
 
4.7 Functional Category Cross-Talks 
 
 
Figure 4.6 Visualization of significantly over-represented GO cross – talk sub-
networks related to Grr1 induced morphological change.  The partial sub-networks 
were constructed by seeding the significantly enriched GO cross-talk sub-network by 
“bud”, “cell projection”, “site of polarized growth”, “asexual reproduction”, and 
“morphogenesis". The top one is for biological process and the bottom one is for 
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cellular component. The numbers and the thickness both denote the enrichment of the 
GO cross-talk pairs in the protein-protein interaction sub-network. The larger the 
number, or the thicker the line, the more enriched the GO pair is. 
 
     To investigate how these Grr1-deletion enriched GO categories are functionally 
associated with each other, we subsequently performed functional category cross-talk 
analysis (for detailed method, see method section 3.7), and identified 287 significant 
over/under-represented GO-GO cross-talks (see appendix 4).  
 
     In particular, the significantly enriched GO categories discovered previously, i.e. 
“bud”, “cell projection”, “site of polarized growth”, “asexual reproduction”, and 
“morphogenesis" are also involved in the significantly enriched GO-GO cross-talk 
pairs. These cross-talk GO categories are functionally related to the yeast bud 
morphological phenotype change induced by Grr1 knock-out perturbation. 
Importantly, some of the GO-GO pairs are highly connected and form the GO-GO 
interaction subnet for Grr1 (Figure 4.6), implying that Grr1 perturbation may affect 
some specific biological processes or cellular components through a small core group 
of proteins. Further more, we also observe that microtube associated complex is highly 
connected to other GO categories in the GO cross-talk sub-network that are related to 
Grr1 induced morphological change. This intrigues us since there is no previously 
known role for Grr1 in microtubule related processes.  
 
      Drill-down analysis of the group of proteins involved in the GO cross-talk sub-
network might help biologists discover the proteins that significantly contribute to the 
Grr1 perturbed morphological phenotype change. 
 
4.8 Scoring of Significant Proteins in the Sub-Network 
     We further performed significant proteins ranking analysis, with the hope of 
isolating important proteins that contribute to Grr1's possible new function that we 
discovered earlier by our ontology-driven network-enabled approach. 
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     Based on the connectivity and the confidence of the protein-protein interactions, we 
ranked significant seed proteins (for detail of the method, see section 3.10). Table 4.6 
shows the top-ranked 20 proteins among 184 seed proteins.  
Table 4.6 Ranking analysis of the significant proteins. Only 20 top-ranked proteins 
were listed here due to the space. 
Rank Score ORF Gene Symbol Fold Change (Grr1─ vs wt) 
1 4.1826 YGL167C PMR1 0.250 
2 3.9453 YPR141C KAR3 5.970 
3 3.8658 YNL298W CLA4 0.202 
4 3.0236 YPL174C NIP100 0.111 
5 2.8646 YOR261C RPN8 0.33 
6 2.8301 YNL233W BNI4 5.31 
7 2.784 YML008C ERG6 0.129 
8 2.7606 YDR155C CPR1 0.524 
9 2.6697 YNL244C SUI1 4.224 
10 2.6495 YKL173W SNU114 0.409 
11 2.6329 YKR054C DYN1 39.224 
12 2.6311 YMR309C NIP1 13.115 
13 2.6219 YJL148W RPA34 0.129 
14 2.5001 YGL055W OLE1 6.486 
15 2.3706 YBL047C EDE1 0.343 
16 2.3508 YBR152W SPP381 4.658 
17 2.328 YDL006W PTC1 0.229 
18 2.3236 YGL112C TAF6 0.4029 
19 2.3079 YLR087C CSF1 6.4511 
20 2.2101 YOR290C SNF2 0.1812 
      
Later, we isolated the actual proteins from the top ranked protein list that mapped 
to the GO component term "microtubule associated complex". The analysis revealed that 
two of the most highly connected proteins, Nip100 and Dyn1. Both proteins also 
represented most extensively changed proteins in the network: Dyn1 protein levels 
were observed to increase in the Grr1 mutant ~ 40 fold while Nip100 protein levels 
were observed to decrease ~10 fold in the analysis. Nip100 is part of the dynactin 
complex[94] where it is thought to act as a tether for Dynein, encoded by Dyn1. Thus 
we probed the relationship between Grr1 and Nip100. Figure 4.7 shows protein 
interaction sub-network seeded by Grr1, Dyn1, and Nip100, where Grr1 connects to 
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Nip100 through Bzz1 and Tub3. Grr1 connects to Dyn1 through Cdc12 and Pac10. 
We hypothesized that Grr1‟s influence on the GO component microtubule associated 
complex could be possibly through one or more of these bridge proteins such as Bzz1. 
The biological experiments are being conducted by our biology group to validate this 
hypothesis. 
 
 
Figure 4.7 Protein interaction sub-network seeded by Grr1, Dyn1, and Nip100. 
Node colors: Red = protein level > 2 fold, Bright blue = -2>= protein level <=2, Grey 
= no detection, Green = protein level <-2. Line colors: Red = Synthetic Lethality, Pink 
= Synthetic Growth Defect, Light Blue = Two Hybrid or Affinity Capture MS, Dark 
Blue = Reconstituted Complex or Affinity Capture Western, Green = Synthetic 
Rescue, Purple = Dosage Rescue, Orange = Phenotypic Suppression, Yellow = 
Phenotypic Enhancement. This figure was provided by Josh Heyen. 
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     Through ranking analysis, we also further validated our ontology-driven network-
enabled approach.  Kar3, a kinesin-like nuclear fusion protein, is ranked at the second 
place in the table. It belongs to gene ontology categories “sexual reproduction” (level 
3 biological process) and “intracellular” (level 3 cellular component). The third top-
ranked protein Cla4, a protein kinase, can be mapped to GO categories “asexual 
reproduction”  at level 4 biological process, and “budding cell apical bud growth”, 
“cell communication”, “metabolism”, and “morphogenesis” at level 3 biological 
process. All of the GO categories mapped by these proteins have been shown to be 
important in Grr1 perturbation induced morphological changes through our ontology-
driven and network-enabled approach based analysis.  
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5. CONCLUSIONS 
 
     In the current study, we developed a systems biology approach to analyze the 
proteomics data. We applied this novel approach to two case studies: human ovarian 
cancer drug resistance study and yeast Grr1 knock-out study.  
 
     The identified differentially expressed proteins formed basic dataset – seed proteins 
of our case studies. We used the seed proteins to construct our protein-protein sub-
network. Then we analyzed the core protein-protein interaction sub-network feature. 
Both human ovarian cancer drug resistance related and yeast Grr1 knock-out sub-
networks showed high connectivity feature. After we mapped the proteins and protein-
protein interactions to GO annotations and constructed GO–GO cross-talk sub-
networks, we performed statistical testing to find significantly enriched over / under-
represented GO categories and GO-GO cross-talk categories. The visualization tools 
“Spotfire” and “Proteolense” were used to aid in the analysis.  
 
     Our approach has been validated in the two case studies by comparing our 
discoveries with existing findings. Some new insights were obtained.  
 
     In the first case study, we observed that cellular physiological process is 
significantly activated in drug-resistant cell lines, and this response arises from 
endogenous, abiotic, and stress-related signals. Our studies also showed that cisplatin 
resistant cell line demonstrated unusually high level of protein-binding activities, and 
a broad spectrum of cross-the-board drug-binding and nucleotide-binding mechanisms 
are all activated.  
 
     In the second case study, we observed that a subset of significantly over-
represented enriched GO categories is highly connected in the GO sub-network, which 
implies that Grr1 induced morphological phenotype change might be resulted from a 
small core group of proteins. We hypothesized Grr1's new role in microtubule related 
processes based on the high connectivity of microtubule associated complex with 
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other GO categories for Grr1's known functions. We further performed ranking 
analysis of the significant seed proteins based on their connectivities and reliabilities 
of the interactions in the sub-network. The ranking analysis further validated our 
findings revealed by the ontology-driven network-enabled approach. These biological 
discoveries support the significance of developing a common framework of evaluating 
functional genomics and proteomics data, using networks and systems approaches.  
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6. DISCUSSIONS 
 
     Molecular biology focuses the mechanistic study of biological phenomena. One of 
its strengths is to concentrate on the actions of a small number of genes without being 
distracted by the complex biological milieu in which they are found. However, in 
terms of a series of binary interactions or when pathways become complex and many 
genes work together, using molecular biology to model function shows its weakness. 
In this case, more network-level understanding is required. In this study, we showed 
that the key to interpreting omics data is a systems biology approach, which is both 
hypothesis-driven and data-driven, with the ultimate goal of integrating multi-
dimensional biological signals at molecular signaling network levels.  It is important 
to note that systems biology approach and the traditional molecular biology approach 
should complement each other in order to achieve a deep understanding of the 
molecular mechanisms. The systems biology approach is not a replacement of the 
traditional approach. 
 
     In the present study, we described a novel systems biology approach to integrate 
omics data with both GO annotation and protein interaction networks and its 
application in two proteomic case studies. The whole proteome of two cellular 
conditions of yeast or human cells were interrogated using LC-MS/MS. A 
differentially expressed protein lists were obtained by statistical analyses controlling 
false discovery rate. We obtained 114 and 184 significantly over- or under-expressed 
proteins for our two case studies, respectively. The mass spectrometer-based 
proteomics analysis is one of the major techniques recently developed to examine 
thousands of proteins simultaneously. Since it directly analyzes the protein level and 
protein modifications, the mass spectrometer- based proteomics provides more direct 
explanations for cellular processes involving multiple protein components. However, 
the current proteomics analysis was unable to detect and quantify an entire proteome 
and has low sensitivity to the low-abundant proteins such as Grr1, which may play 
critical roles in many important biological processes.  
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     The large volume of differentially expressed proteins derived from the proteomics 
and microarray studies provide us the opportunity for investigating the biological 
function at the systems level. However, the protein lists themselves offers very limited 
clues to our understanding of the biological processes that underlie cisplatin resistance 
of human ovarian cancer cells or abnormal phenotype that is associated with Grr1 
deletion. Most of the identified significant differentially regulated proteins are not 
obviously related to the known function of Grr1 or drug resistance. As our first 
attempt to understand the function of our protein list, we performed ontology-based 
analysis, which is now widely used in data mining of functional genomic data as well 
as proteomics data. Gene ontology annotation is an important milestone on 
possibilities to handle and link biological knowledge with gene profiles identified in 
functional genomics and proteomics analysis. 
 
     Nevertheless, mapping differentially expressed protein list onto ontology provided 
only limited information to our understanding of the biological processes associated 
with cellular conditions. For example, our GO annotation analysis of Grr1-deletion 
affected protein list leads to identification of three enriched GO terms after applying 
certain filter: eukaryotic 43S preinitiation complex, lipid transporter activity, 
oxidoreductase activity, none seems to be clearly associated with known function of 
Grr1. Thus, although GO-based analysis proved to be useful in interpretation of the 
gene profiling experiments using microarray[95, 96], this technique on its own provide 
only limited information for our understanding of biological function at the systems 
level.  
 
     Another important approach for interpretation of omics data is network-based 
analysis. Since most biological characteristics arise from complex interactions 
between the cellular constitutes such as proteins, mapping changed proteins identified 
onto protein network will place these proteins in a broader biological context, thereby 
facilitating the understanding of the structure and function of living cells. In our yeast 
case study, we mapped our 184 proteins into protein interaction database and ranked 
the importance of these proteins according to the number of their immediate 
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connectivity and the reliability score calculated using a formula. We hypothesized that 
the most highly connected proteins in the sub-network may represent proteins that 
may be mostly directly affected by Grr1 gene deletion. Intriguingly, two of the 20 top-
ranked proteins, Nip100 and Dyn1 are genetically and physically connected with each 
other (Figure 4.7). The physical association of Grr1 with Nip100 is through Bzz1, 
which appears in our extended protein ranking list. As Nip100 and Dyn1 are a part of 
the microtubule components, Grr1 may exert its function though its influence on its 
immediate target Bzz1. This hypothesis warrants a detailed study in the future. 
 
     One of the distinct features of our systems biology approach is to bring the gene 
ontology category concept into the context of protein-protein interaction network and 
use it for omics data analysis. We hypothesized that the limited number of changed 
proteins identified through proteomics may actually be connected within Grr1 sub-
network. These changed proteins may exert their function by influencing the protein 
networks that they are involved in. We thus expand our interest of proteins to include 
those proteins that directly interact with our changed proteins. To understand the 
biological function of these expanded protein list, we then mapped the protein list onto 
gene ontology terms and identified significantly enriched GO terms. Through this 
approach, we found about 40 significantly enriched GO terms by applying a certain 
filter. Strikingly, 10 of the enriched GO-terms could be ascribed to Grr1 or its target 
proteins (Figure 4.5) according to previous publications. Thus, our ontology-driven 
and protein network-enabled approach can not only be used to validate existing 
knowledge, but also have the potential to generate the hypothesis for future 
investigation. 
 
     In our approach, we also explored GO-GO cross-talks and identified Grr1-deletion 
associated GO-GO cross talks. This information further extends our understanding of 
the connection of multiple processes induced by gene deletion or other stress 
conditions. We also demonstrated that functional 2-dimensional matrix and protein 
interaction network visualization tool may significantly facilitate the biologists to form 
their hypotheses. 
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     Our systems biology approach provides a framework for further improvement in 
the future. First, our analysis is currently based on proteomics data only. The method 
described here is readily applicable to microarray data analysis. We expect to gain 
more in-depth understanding of the Grr1 function by incorporation of published Grr1 
microarray data into our analysis. Because the relationship between transcription and 
translation is likely to vary based on the individual gene/protein, it may not be realistic 
to expect a high degree of correlation between protein and RNA levels when 
attempting to correlate dynamic change in RNA with a static picture of proteins. 
Combination of genomics and proteomics data requires further development of current 
approach. Second, our network-based analysis focuses on the functional significance 
of changed proteins through protein-protein interaction analysis. We made no attempt 
to understand how the changed proteins are regulated by genetic or environmental 
stress. One of the future directions is to incorporate gene regulatory network analysis 
in order to identify regulatory relationships among large numbers of genes that form a 
network representation of the underlying regulatory processes. Finally, our current 
model needs fine adjustment to provide elegant interpretation of omics data. For 
example, the validity of ranking model needs further investigation. Drill-down of GO 
categories analysis may provide further details for interpretation of biological 
consequences induced by genetic or environmental stresses. 
 
     In summary, our ontology-driven network-enabled systems biology approach 
provides in-depth understanding of cellular functions and creates a robust concept 
framework for further improvement in the future. 
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7. Appendices 
 
Appendix 1. ERD diagram for Oracle schema Sysbio. For details, see [21]. 
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Appendix 2. Uniprot ID mappings for 119 differentially expressed seed proteins 
in ovarian cancer drug resistance study. 
 
UNIPROTID 
ANKS1_HUMAN 
1433T_HUMAN 
1433Z_HUMAN 
1433E_HUMAN 
1433F_HUMAN 
ACTN1_HUMAN 
AL3A1_HUMAN 
AL3A1_HUMAN 
AKAP9_HUMAN 
AL1A1_HUMAN 
CBX3_HUMAN 
DEST_HUMAN 
CENPE_HUMAN 
CNN2_HUMAN 
CRIP2_HUMAN 
CRTC_HUMAN 
E41L1_HUMAN 
FKBP4_HUMAN 
6PGD_HUMAN 
ABCG1_HUM AN 
ACADM_HUMAN 
DOCK4_HUMAN 
ANXA3_HUMAN 
B2MG_HUMAN 
DHCA_HUMAN 
CAP1_HUMAN 
ATPA_HUMAN 
ATPB_HUMAN 
CU059_HUMAN 
CYBP_HUMAN 
FA49B_HUMAN 
MDHC_HUMAN 
KCRU_HUMAN 
LPPRC_HUMAN 
GALT3_HUMAN 
HS70L_HUMAN 
HSP76_HUMAN 
GANAB_HUMAN 
IF4H_HUMAN 
HSBP1_HUMAN 
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HS90B_HUMAN 
KAP0_HUMAN 
ETFA_HUMAN 
PHS3_HUMAN 
PP2CG_HUMAN 
PPIA_HUMAN 
PGK1_HUMAN 
PPIB_HUMAN 
PDIA1_HUMAN 
PDIA6_HUMAN 
PARP3_HUMAN 
PADI3_HUMAN 
RS14_HUMAN 
SERA_HUMAN 
SODC_HUMAN 
SFRS2_HUMAN 
SFRS3_HUMAN 
INSI1_HUMAN 
MYLK_HUMAN 
PSB3_HUMAN 
PUR6_HUMAN 
MYH13_HUMAN 
MYL6_HUMAN 
MYL6_HUMAN 
MYL6_HUMAN 
NDK8_HUMAN 
PDCD6_HUMAN 
O2T35_HUMAN 
NDKB_HUMAN 
PCNA_HUMAN 
PLSI_HUMAN 
RL15_HUMAN 
TYSY_HUMAN 
VINC_HUMAN 
UGDH_HUMAN 
S10A1_HUMAN 
ST1A2_HUMAN 
TBA1_HUMAN 
TBA3_HUMAN 
TCP4_HUMAN 
THIL_HUMAN 
THIO_HUMAN 
SMCA5_HUMAN 
 71 
TPIS_HUMAN 
TBA8_HUMAN 
TBAK_HUMAN 
STMN1_HUMAN 
RPA5_HUMAN 
Q12803_HUMAN 
O75935_HUMAN 
O60486_HUMAN 
O14950_HUMAN 
Q6IQ55_HUMAN 
Q6MZM0_HUMAN 
Q6ZSF4_HUMAN 
Q5HYM0_HUMAN 
Q5VVN3_HUMAN 
Q5S007_HUMAN 
Q5VU19_HUMAN 
Q7Z4V5_HUMAN 
Q86XQ2_HUMAN 
Q86WH0_HUMAN 
Q75MT3_HUMAN 
Q9P2M8_HUMAN 
Q9NVS0_HUMAN 
Q9NZI8_HUMAN 
Q9Y2K3_HUMAN 
Q9UPT8_HUMAN 
Q8TBR1_HUMAN 
Q8WU10_HUMAN 
ALDOA_HUMAN 
CH60_HUMAN 
PDIA3_HUMAN 
SEC5_HUMAN 
PSA6_HUMAN 
TBA6_HUMAN 
STMN2_HUMAN 
RL12_HUMAN 
Q96D18_HUMAN 
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Appendix 3. ORFs for 184 differentially expressed seed proteins in Grr1 knock-
out case study 
 
ORF Fold Change 
Q0255 4.15793714718904 
YAL038W 0.545852252758714 
YAR009C 6.05360443593325 
YBL015W 0.328014440120407 
YBL016W 8.14232901955471 
YBL030C 4.28248520447998 
YBL047C 0.34267736598115 
YBL088C 2.49526272717271 
YBL092W 0.483721610343309 
YBR021W 0.157116451158551 
YBR078W 0.23105360448864 
YBR115C 22.25185704536 
YBR136W 4.19593345669184 
YBR148W 1.86570263971014 
YBR149W 0.25000000018879 
YBR152W 4.65804066570279 
YBR169C 6.03512014781145 
YBR214W 0.203327171879698 
YBR218C 8.31792976604813E-02 
YBR225W 4.26987061012334 
YBR231C 9.54316594964094E-02 
YBR233W 12.8927911263819 
YBR241C 2.13537469763711 
YBR263W 0.147874306878216 
YBR272C 2.31265108764462 
YBR275C 4.96736103277175 
YBR286W 2.96785473982758 
YCL011C 2.59830512475747 
YCR065W 0.101522842755918 
YDL006W 0.228887134956306 
YDL019C 9.3956486699021 
YDL058W 9.8820593963859 
YDL075W 2.26719154500437 
YDL127W 5.34195933395087 
YDL131W 2.01603150013112 
YDL154W 5.66956521767448 
YDL176W 0.346494762223967 
YDL239C 0.295748613985256 
YDR035W 0.419114082837675 
YDR058C 4.17638479544648 
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ORF Fold Change 
YDR081C 0.175600739297833 
YDR116C 3.01369863012484 
YDR138W 2.44157937145452 
YDR155C 0.523771152122715 
YDR168W 0.194085027742803 
YDR171W 4.26062846561671 
YDR177W 0.166358595066621 
YDR226W 3.31896375814804 
YDR247W 3.68435004836908 
YDR351W 21.1090573011355 
YDR379W 0.191304347619674 
YDR450W 1.97524910005861 
YDR464W 20.3099999997752 
YDR469W 0.331450044758495 
YDR483W 0.240000000159372 
YER026C 5.84103511998871 
YER042W 6.30314232922456 
YER158C 1.91551565055894 
YER166W 0.273972603027691 
YER176W 0.12628255728794 
YER178W 2.10660620275169 
YFL003C 0.470655774025158 
YFL007W 5.73796369408722 
YFR034C 2.19983883943257 
YGL003C 0.110667072598724 
YGL055W 6.48573742222094 
YGL103W 2.07971802652271 
YGL112C 0.402900886532899 
YGL131C 0.370668815315337 
YGL148W 0.277264325355963 
YGL151W 0.203327171879698 
YGL156W 2.59468170831708 
YGL167C 0.249798549363811 
YGR004W 12.5138632168835 
YGR027C 1.78132111635026 
YGR087C 0.228887134956306 
YGR132C 0.360000000192903 
YGR175C 0.129390018511791 
YGR189C 0.29008863801562 
YGR203W 9.8383973630905 
YGR235C 3.69863013665815 
YGR275W 6.88539741255251 
YGR284C 0.304990757780443 
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ORF Fold Change 
YGR288W 14.1988950288631 
YHL011C 27.3300000004619 
YHL033C 2.45951318287733 
YHR104W 9.14445109656317 
YHR114W 6.39305445942334 
YHR179W 2.63093435531901 
YHR198C 6.46253021778323 
YIL019W 0.12628255728794 
YIL031W 5.01739130432334 
YIL041W 2.31952362986739 
YIL053W 0.345265042503515 
YIL112W 2.50699522170334 
YIL143C 8.91870560378892 
YIL159W 0.265416928466571 
YIR006C 8.86321626617145 
YJL005W 3.2126713688849 
YJL016W 2.38517324759968 
YJL051W 28.3078162776328 
YJL148W 0.129390018511791 
YJL190C 2.31551734904835 
YJL216C 7.52310536012055 
YJL218W 0.175600739297833 
YJR045C 1.81916371834376 
YJR061W 5.96954314750328 
YJR066W 23.0050761405552 
YKL014C 0.434430958041895 
YKL088W 0.306204673567028 
YKL173W 0.40890152098861 
YKL180W 1.9170591930552 
YKL195W 0.394842869081812 
YKL209C 8.1319796956819 
YKR018C 0.173638516204436 
YKR054C 39.2236598928196 
YKR057W 0.308407642817507 
YKR064W 0.258780037223804 
YKR096W 0.177276389876017 
YLL007C 3.64222401278672 
YLL045C 2.45951318287733 
YLL046C 2.20789685726298 
YLL057C 4.59352801929727 
YLR004C 3.08622078989969 
YLR028C 4.13321763210272 
YLR080W 0.173638516204436 
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ORF Fold Change 
YLR087C 6.45107160556459 
YLR148W 4.31103948406353 
YLR179C 12.5138632168835 
YLR191W 0.203045685201405 
YLR276C 7.05175600764816 
YLR376C 0.286506469458886 
YLR422W 0.380221832832661 
YLR450W 5.29578856112268 
YML008C 0.129390018511791 
YML023C 8.44670050774818 
YMR038C 0.234289452235187 
YMR068W 0.378726832817958 
YMR079W 0.339999999966919 
YMR096W 0.323475046523754 
YMR108W 0.522342689654229 
YMR133W 0.249537892567939 
YMR145C 3.06832708199654 
YMR231W 0.320883101002656 
YMR295C 0.31423290183668 
YMR309C 13.1146025881953 
YMR313C 0.217566478816452 
YNL073W 4.1095890411034 
YNL079C 0.303703534315121 
YNL121C 0.175600739297833 
YNL160W 8.4011090582411 
YNL218W 0.464296173029536 
YNL221C 2.35702717777939 
YNL233W 5.31000000022657 
YNL241C 0.304990757780443 
YNL244C 4.22365988910108 
YNL298W 0.201450443110585 
YNL313C 14.4269870612683 
YNR031C 8.90355330013963 
YOL056W 2.57856567271875 
YOL059W 2.97340854177039 
YOL060C 3.528963333553 
YOL081W 0.438552809930963 
YOL127W 0.46438538789387 
YOR048C 4.43190975024723 
YOR129C 3.11039484306185 
YOR136W 0.160000000126762 
YOR172W 0.145044319229564 
YOR187W 0.110905730058634 
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ORF Fold Change 
YOR191W 10.2233502548427 
YOR261C 0.330000000092788 
YOR290C 0.181206660197459 
YPL007C 27.7043478253533 
YPL113C 7.07182320476699 
YPL174C 0.110497237621271 
YPL231W 0.444474029156303 
YPL239W 4.99999999958532 
YPL248C 0.149960536676909 
YPL255W 12.3475046219541 
YPR004C 0.323475046523754 
YPR117W 12.2912449348497 
YPR134W 0.55600322290172 
YPR141C 5.97042513829489 
YPR186C 2.90894439963127 
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Appendix 4 Significantly over/under-represented GO cross-talk pairs for Grr1 
knock-out case study 
 
TYPE GO term 1 GO term 2 GO ID1 GO ID2 
F channel or pore class transporter 
activity 
ion transporter activity 15267 15075 
F ATPase activity\, coupled to 
movement of substances 
ion transporter activity 43492 15075 
F ion binding ion transporter activity 43167 15075 
F hydrolase activity ion transporter activity 16787 15075 
F transferase activity ion transporter activity 16740 15075 
F alcohol transporter activity ion transporter activity 15665 15075 
F peptide transporter activity ion transporter activity 15197 15075 
F ion transporter activity ion transporter activity 15075 15075 
C intracellular organelle ubiquitin ligase complex 43229 151 
C intracellular ubiquitin ligase complex 5622 151 
C membrane-bound organelle ubiquitin ligase complex 43227 151 
F ATPase activity\, coupled to 
movement of substances 
peptide transporter activity 43492 15197 
F ATPase activity\, coupled to 
movement of substances 
channel or pore class 
transporter activity 
43492 15267 
F ATPase activity\, coupled to 
movement of substances 
alcohol transporter activity 43492 15665 
F nucleobase\, nucleoside\, nucleotide 
and nucleic acid transporter activity 
nucleobase\, nucleoside\, 
nucleotide and nucleic acid 
transporter activity 
15932 15932 
F lyase activity nucleobase\, nucleoside\, 
nucleotide and nucleic acid 
transporter activity 
16829 15932 
C intracellular organelle membrane 43229 16020 
C immature spore membrane 42763 16020 
C pyruvate dehydrogenase complex membrane 45254 16020 
C external encapsulating structure membrane 30312 16020 
C non-membrane-bound organelle membrane 43228 16020 
C membrane-bound organelle membrane 43227 16020 
P cellular physiological process cell growth 50875 16049 
C eukaryotic 48S initiation complex eukaryotic 43S preinitiation 
complex 
16283 16282 
C eukaryotic 43S preinitiation 
complex 
eukaryotic 43S preinitiation 
complex 
16282 16282 
C non-membrane-bound organelle eukaryotic 43S preinitiation 
complex 
43228 16282 
C non-membrane-bound organelle eukaryotic 48S initiation 
complex 
43228 16283 
C intracellular organelle hydrogen-translocating V-
type ATPase complex 
43229 16471 
F ion binding oxidoreductase activity 43167 16491 
 78 
TYPE GO term 1 GO term 2 GO ID1 GO ID2 
F transferase activity oxidoreductase activity 16740 16491 
C RNA polymerase complex DNA-directed RNA 
polymerase II\, holoenzyme 
30880 16591 
F ion binding nucleotide binding 43167 166 
F receptor signaling protein activity nucleotide binding 5057 166 
F carrier activity nucleotide binding 5386 166 
F electron transporter activity nucleotide binding 5489 166 
F protein binding nucleotide binding 5515 166 
F ATPase activity\, coupled to 
movement of substances 
nucleotide binding 43492 166 
F ion transporter activity nucleotide binding 15075 166 
F transferase activity nucleotide binding 16740 166 
F cyclase activity nucleotide binding 9975 166 
F GTPase regulator activity transferase activity 30695 16740 
F ligase activity transferase activity 16874 16740 
F ion binding transferase activity 43167 16740 
F lyase activity transferase activity 16829 16740 
F hydrolase activity transferase activity 16787 16740 
F ATPase activity\, coupled to 
movement of substances 
transferase activity 43492 16740 
F ion binding hydrolase activity 43167 16787 
F ATPase activity\, coupled to 
movement of substances 
hydrolase activity 43492 16787 
F hydrolase activity hydrolase activity 16787 16787 
F GTPase regulator activity lyase activity 30695 16829 
F vitamin binding lyase activity 19842 16829 
F ion binding ligase activity 43167 16874 
C intracellular organelle exosome (RNase complex) 43229 178 
C intracellular exosome (RNase complex) 5622 178 
P regulation of physiological process sexual reproduction 50791 19953 
P cellular physiological process sexual reproduction 50875 19953 
P negative regulation of biological 
process 
sexual reproduction 48519 19953 
P regulation of cellular process sexual reproduction 50794 19953 
P reproductive physiological process sexual reproduction 50876 19953 
P non-developmental growth sexual reproduction 48590 19953 
P regulation of cellular process asexual reproduction 50794 19954 
P localization asexual reproduction 51179 19954 
P asexual reproduction asexual reproduction 19954 19954 
P cell differentiation asexual reproduction 30154 19954 
P reproductive physiological process asexual reproduction 50876 19954 
P regulation of physiological process asexual reproduction 50791 19954 
P cellular physiological process asexual reproduction 50875 19954 
P non-developmental growth asexual reproduction 48590 19954 
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TYPE GO term 1 GO term 2 GO ID1 GO ID2 
C membrane-bound organelle cell fraction 43227 267 
C intracellular cell fraction 5622 267 
C intracellular organelle cell fraction 43229 267 
P reproductive physiological process cell differentiation 50876 30154 
P cell differentiation cell differentiation 30154 30154 
P filamentous growth cell differentiation 30447 30154 
P non-developmental growth cell differentiation 48590 30154 
P cellular physiological process cell differentiation 50875 30154 
C intracellular organelle external encapsulating 
structure 
43229 30312 
C membrane-bound organelle external encapsulating 
structure 
43227 30312 
C non-membrane-bound organelle site of polarized growth 43228 30427 
C intracellular organelle site of polarized growth 43229 30427 
C site of polarized growth site of polarized growth 30427 30427 
P reproductive physiological process filamentous growth 50876 30447 
P non-developmental growth filamentous growth 48590 30447 
C ribonucleoprotein complex ribonucleoprotein complex 30529 30529 
C intracellular organelle ribonucleoprotein complex 43229 30529 
C intracellular organelle Noc complex 43229 30689 
F ion binding GTPase regulator activity 43167 30695 
F ATPase activity\, coupled to 
movement of substances 
GTPase regulator activity 43492 30695 
C non-membrane-bound organelle RNA polymerase complex 43228 30880 
C intracellular organelle transcription export complex 43229 346 
C intracellular transcription export complex 5622 346 
C non-membrane-bound organelle transcription export complex 43228 346 
C membrane-bound organelle transcription export complex 43227 346 
F RNA polymerase II transcription 
factor activity 
nucleic acid binding 3702 3676 
F nucleic acid binding nucleic acid binding 3676 3676 
F cyclase activity nucleic acid binding 9975 3676 
F protein binding nucleic acid binding 5515 3676 
F hydrolase activity nucleic acid binding 16787 3676 
F translation factor activity\, nucleic 
acid binding 
nucleic acid binding 8135 3676 
F electron transporter activity nucleic acid binding 5489 3676 
P cellular physiological process regulation of growth 50875 40008 
P regulation of physiological process regulation of gene 
expression\, epigenetic 
50791 40029 
P regulation of gene expression\, 
epigenetic 
regulation of gene 
expression\, epigenetic 
40029 40029 
P negative regulation of biological 
process 
regulation of gene 
expression\, epigenetic 
48519 40029 
P cellular physiological process regulation of gene 50875 40029 
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TYPE GO term 1 GO term 2 GO ID1 GO ID2 
expression\, epigenetic 
P regulation of cellular process regulation of gene 
expression\, epigenetic 
50794 40029 
P regulation of cellular process homeostasis 50794 42592 
P cellular physiological process homeostasis 50875 42592 
P regulation of physiological process homeostasis 50791 42592 
C intracellular organelle immature spore 43229 42763 
C membrane-bound organelle immature spore 43227 42763 
C non-membrane-bound organelle immature spore 43228 42763 
C membrane-bound organelle cell projection 43227 42995 
C intracellular organelle cell projection 43229 42995 
F ion binding ion binding 43167 43167 
F ATPase activity\, coupled to 
movement of substances 
ion binding 43492 43167 
C pyruvate dehydrogenase complex membrane-bound organelle 45254 43227 
C membrane-bound organelle membrane-bound organelle 43227 43227 
C organelle lumen membrane-bound organelle 43233 43227 
C non-membrane-bound organelle non-membrane-bound 
organelle 
43228 43228 
C intracellular organelle non-membrane-bound 
organelle 
43229 43228 
C organelle lumen intracellular organelle 43233 43229 
C ubiquinol-cytochrome-c reductase 
complex 
intracellular organelle 45285 43229 
C respiratory chain complex III intracellular organelle 45275 43229 
C pyruvate dehydrogenase complex intracellular organelle 45254 43229 
F ATPase activity\, coupled to 
movement of substances 
ATPase activity\, coupled to 
movement of substances 
43492 43492 
F cyclase activity helicase activity 9975 4386 
F ATPase activity\, coupled to 
movement of substances 
helicase activity 43492 4386 
F ion transporter activity helicase activity 15075 4386 
F transferase activity helicase activity 16740 4386 
P cellular physiological process negative regulation of 
biological process 
50875 48519 
P regulation of physiological process negative regulation of 
biological process 
50791 48519 
P non-developmental growth negative regulation of 
biological process 
48590 48519 
P regulation of cellular process negative regulation of 
biological process 
50794 48519 
P regulation of enzyme activity negative regulation of 
biological process 
50790 48519 
F receptor signaling protein activity enzyme inhibitor activity 5057 4857 
P localization non-developmental growth 51179 48590 
P regulation of physiological process non-developmental growth 50791 48590 
 81 
TYPE GO term 1 GO term 2 GO ID1 GO ID2 
P cellular physiological process non-developmental growth 50875 48590 
P non-developmental growth non-developmental growth 48590 48590 
P reproductive physiological process non-developmental growth 50876 48590 
P regulation of cellular process non-developmental growth 50794 48590 
F ion binding receptor activity 43167 4872 
C ribonucleoprotein complex proteasome complex (sensu 
Eukaryota) 
30529 502 
C intracellular organelle proteasome complex (sensu 
Eukaryota) 
43229 502 
C proteasome regulatory particle 
(sensu Eukaryota) 
proteasome complex (sensu 
Eukaryota) 
5838 502 
C intracellular proteasome complex (sensu 
Eukaryota) 
5622 502 
C non-membrane-bound organelle proteasome complex (sensu 
Eukaryota) 
43228 502 
F transferase activity receptor signaling protein 
activity 
16740 5057 
F ion binding receptor signaling protein 
activity 
43167 5057 
P cellular physiological process regulation of enzyme activity 50875 50790 
P regulation of enzyme activity regulation of enzyme activity 50790 50790 
P regulation of physiological process regulation of physiological 
process 
50791 50791 
P localization regulation of physiological 
process 
51179 50791 
P regulation of cellular process regulation of physiological 
process 
50794 50791 
P regulation of cellular process regulation of cellular process 50794 50794 
P localization regulation of cellular process 51179 50794 
P reproductive physiological process cellular physiological process 50876 50875 
P localization localization 51179 51179 
F ATPase activity\, coupled to 
movement of substances 
lipid transporter activity 43492 5319 
F hydrolase activity carrier activity 16787 5386 
F transferase activity carrier activity 16740 5386 
F ATPase activity\, coupled to 
movement of substances 
carrier activity 43492 5386 
F ion transporter activity carrier activity 15075 5386 
F alcohol transporter activity carrier activity 15665 5386 
F channel or pore class transporter 
activity 
carrier activity 15267 5386 
F ion transporter activity intracellular transporter 
activity 
15075 5478 
F ATPase activity\, coupled to 
movement of substances 
intracellular transporter 
activity 
43492 5478 
F transferase activity electron transporter activity 16740 5489 
 82 
TYPE GO term 1 GO term 2 GO ID1 GO ID2 
F ligase activity electron transporter activity 16874 5489 
F ion binding electron transporter activity 43167 5489 
F transferase activity protein binding 16740 5515 
F cyclase activity protein binding 9975 5515 
C proteasome regulatory particle 
(sensu Eukaryota) 
intracellular 5838 5622 
C ribonucleoprotein complex intracellular 30529 5622 
C ubiquinol-cytochrome-c reductase 
complex 
intracellular 45285 5622 
C mRNA cleavage factor complex intracellular 5849 5622 
C respiratory chain complex III intracellular 45275 5622 
C histone methyltransferase complex intracellular 35097 5622 
C mitochondrial inner membrane 
presequence translocase complex 
intracellular 5744 5622 
C immature spore intracellular 42763 5622 
C transcription factor complex intracellular 5667 5622 
C pyruvate dehydrogenase complex intracellular 45254 5622 
C cell projection intracellular 42995 5622 
C Noc complex intracellular 30689 5622 
C site of polarized growth intracellular 30427 5622 
C bud intracellular 5933 5622 
C eukaryotic 43S preinitiation 
complex 
intracellular 16282 5622 
C external encapsulating structure intracellular 30312 5622 
C hydrogen-translocating V-type 
ATPase complex 
intracellular 16471 5622 
C microtubule associated complex intracellular 5875 5622 
C unlocalized protein complex transcription factor complex 5941 5667 
C intracellular organelle transcription factor complex 43229 5667 
C immature spore transcription factor complex 42763 5667 
C membrane-bound organelle transcription factor complex 43227 5667 
C transcription factor complex transcription factor complex 5667 5667 
C DNA-directed RNA polymerase II\, 
holoenzyme 
transcription factor complex 16591 5667 
C membrane-bound organelle mitochondrial inner 
membrane presequence 
translocase complex 
43227 5744 
C intracellular organelle mitochondrial inner 
membrane presequence 
translocase complex 
43229 5744 
C membrane-bound organelle proteasome regulatory particle 
(sensu Eukaryota) 
43227 5838 
C intracellular organelle proteasome regulatory particle 
(sensu Eukaryota) 
43229 5838 
C intracellular organelle mRNA cleavage factor 
complex 
43229 5849 
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TYPE GO term 1 GO term 2 GO ID1 GO ID2 
C membrane-bound organelle mRNA cleavage factor 
complex 
43227 5849 
C intracellular organelle microtubule associated 
complex 
43229 5875 
C site of polarized growth microtubule associated 
complex 
30427 5875 
C membrane microtubule associated 
complex 
16020 5875 
C membrane-bound organelle microtubule associated 
complex 
43227 5875 
C bud microtubule associated 
complex 
5933 5875 
C non-membrane-bound organelle microtubule associated 
complex 
43228 5875 
C cell projection microtubule associated 
complex 
42995 5875 
C site of polarized growth bud 30427 5933 
C non-membrane-bound organelle bud 43228 5933 
C bud bud 5933 5933 
C intracellular organelle bud 43229 5933 
P regulation of gene expression\, 
epigenetic 
response to stress 40029 6950 
P asexual reproduction response to stress 19954 6950 
P negative regulation of biological 
process 
response to stress 48519 6950 
P response to abiotic stimulus response to stress 9628 6950 
P non-developmental growth response to stress 48590 6950 
P morphogenesis response to stress 9653 6950 
P regulation of physiological process response to stress 50791 6950 
P cell communication response to stress 7154 6950 
P regulation of enzyme activity response to stress 50790 6950 
P regulation of cellular process response to stress 50794 6950 
P cellular physiological process response to stress 50875 6950 
P response to endogenous stimulus response to stress 9719 6950 
P negative regulation of biological 
process 
cell communication 48519 7154 
P non-developmental growth cell communication 48590 7154 
P positive regulation of biological 
process 
cell communication 48518 7154 
P cell differentiation cell communication 30154 7154 
P regulation of enzyme activity cell communication 50790 7154 
P response to abiotic stimulus cell communication 9628 7154 
P cellular physiological process cell communication 50875 7154 
P regulation of cellular process cell communication 50794 7154 
P cell communication cell communication 7154 7154 
P sexual reproduction cell communication 19953 7154 
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TYPE GO term 1 GO term 2 GO ID1 GO ID2 
P metabolism cell communication 8152 7154 
P morphogenesis cell communication 9653 7154 
P reproductive physiological process cell communication 50876 7154 
P regulation of physiological process cell communication 50791 7154 
P asexual reproduction cell communication 19954 7154 
P aging cell communication 7568 7154 
P death cell communication 16265 7154 
P response to endogenous stimulus aging 9719 7568 
P cellular physiological process locomotory behavior 50875 7626 
F cyclase activity enzyme activator activity 9975 8047 
F ligase activity translation factor activity\, 
nucleic acid binding 
16874 8135 
F transferase activity translation factor activity\, 
nucleic acid binding 
16740 8135 
P homeostasis metabolism 42592 8152 
P asexual reproduction metabolism 19954 8152 
P regulation of enzyme activity metabolism 50790 8152 
P regulation of cellular process metabolism 50794 8152 
P regulation of gene expression\, 
epigenetic 
metabolism 40029 8152 
P regulation of physiological process metabolism 50791 8152 
P response to abiotic stimulus metabolism 9628 8152 
P morphogenesis metabolism 9653 8152 
P negative regulation of biological 
process 
metabolism 48519 8152 
P response to endogenous stimulus metabolism 9719 8152 
P sexual reproduction metabolism 19953 8152 
P reproductive physiological process metabolism 50876 8152 
P non-developmental growth metabolism 48590 8152 
F ion binding lipid binding 43167 8289 
F ion transporter activity protein transporter activity 15075 8565 
F ATPase activity\, coupled to 
movement of substances 
protein transporter activity 43492 8565 
F transferase activity small protein conjugating 
enzyme activity 
16740 8639 
P regulation of enzyme activity response to abiotic stimulus 50790 9628 
P cellular physiological process response to abiotic stimulus 50875 9628 
P sexual reproduction response to abiotic stimulus 19953 9628 
P asexual reproduction response to abiotic stimulus 19954 9628 
P response to abiotic stimulus response to abiotic stimulus 9628 9628 
P reproductive physiological process response to abiotic stimulus 50876 9628 
P negative regulation of biological 
process 
response to abiotic stimulus 48519 9628 
P non-developmental growth response to abiotic stimulus 48590 9628 
P cellular physiological process morphogenesis 50875 9653 
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TYPE GO term 1 GO term 2 GO ID1 GO ID2 
P asexual reproduction morphogenesis 19954 9653 
P non-developmental growth morphogenesis 48590 9653 
P regulation of cellular process response to endogenous 
stimulus 
50794 9719 
P regulation of physiological process response to endogenous 
stimulus 
50791 9719 
P response to endogenous stimulus response to endogenous 
stimulus 
9719 9719 
P death response to endogenous 
stimulus 
16265 9719 
P asexual reproduction response to endogenous 
stimulus 
19954 9719 
P regulation of gene expression\, 
epigenetic 
response to endogenous 
stimulus 
40029 9719 
P negative regulation of biological 
process 
response to endogenous 
stimulus 
48519 9719 
P non-developmental growth response to endogenous 
stimulus 
48590 9719 
P cellular physiological process response to endogenous 
stimulus 
50875 9719 
F GTPase regulator activity cyclase activity 30695 9975 
F transferase activity cyclase activity 16740 9975 
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